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Introduction and outline of the thesis

Epidemiology
For lung cancer, routine mortality statistics have confirmed the clinical impression that 
the disease became more frequent during the first half of the 20th century. Changes in 
tobacco smoking resulted in changes in the frequency of lung cancer. Tobacco smoking is 
well established as the main cause of lung cancer and about 90% of cases are thought to be 
tobacco related. It is the most commonly diagnosed cancer worldwide with 1.35 million new 
cases in 2002, representing 12.4% of all new cancers. It was also the most common cause of 
death from cancer, with 1.18 million deaths, or 17.6% of the world total.[1] 
In the Netherlands lung cancer is still one of the most common cancer in males. On the basis 
of the 2000 figures of the Netherlands, the incidence of lung cancer was 79.8 in men and 
27 in women per 100.000 per year. Males who have not died from other causes before the 
age of 75 run a 6.72 percent risk of developing lung cancer before the age of 75 (vs. 2.47% 
in females).[2] Malignant lung tumours are grossly categorised into two groups based on 
their morphologic characteristics: small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC). The majority of lung cancer patients have tumours histologically classified as NSCLC 
(84%).[3] 
Prognosis of NSCLC
Despite improved knowledge of therapy and treatment strategies, the prognosis of patients 
with NSCLC has not improved significantly over the last decades. Depending on the results 
of staging procedures, curative surgery is attempted in 30-50%. Nevertheless, survival rates 
for so-called ‘resectable’ lung cancer (stage I-IIIA) vary between 15 and 80% at five years. It 
is estimated that at presentation about 30% of patients has locoregionally advanced disease 
and about 40% has disseminated disease. The prognosis of unresectable lung cancer is poor. 
The 1-year survival rate varies between 10-15%, the 5-year survival of advanced disease 
approaches zero (Table 1).
Clinical evaluation of lung cancer
Patients suspected of having lung cancer undergo several diagnostic procedures to achieve 
a histological diagnosis and final stage assignment. The modality selected to diagnose lung 
cancer is based on size and location of the primary tumour, the presence of metastatic 
spread, and the anticipated treatment plan. The main goals in selecting a specific diagnostic 
modality are: (1) to maximise the yield of the selected procedure for both diagnosis and 
staging; and (2) to avoid unnecessary invasive tests for the patient, with special attention to 
the projected treatment plan. 
Determining the diagnosis of the primary tumour, the extent of spread to regional or distant 
lymph nodes or to other metastatic sites follows two major routes. The first involves obtaining 
tissue and the measurement of extent of disease which incorporates uniform anatomic criteria 
of the international tumour, node, metastasis (TNM) staging system (Table 1).[4] It includes 
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Tumour stage
Tx Presence of malignant cells, no tumour visible
T0 No primary tumour
TIS Carcinoma in situ
T1 Tumour < 3.0 cm in size, no invasion beyond the lobar bronchus
T2 Tumour > 3.0 cm in size; distal atelectasis; involvement of the main bronchus > 2.0 
cm distal to the carina; or invades the visceral pleura
T3 Tumour of any size that invades the chest wall, diaphragm, mediastinal pleura, 
pericard, or main bronchus < 2.0 cm distal to the main bronchus; or associated 
atelectasis of the entire lung
T4 Tumour of any size that invades medidiastinum, the heart, great vessels, 
esophagus, vertebral body, or carina; the presence of malignant pleural/pericard 
effusion; or separate tumour nodules in the same lobe
Nodal Stage
NX Regional lymph nodes cannot be assessed
N0 No lymph node metastasis
N1 Ipsilateral peribronchial or hilar lymph nodes
N2 Involvement of ipsolateral mediastinal and/or subcarinal lymph nodes
N3 Involvement of contralateral or supraclavicular lymph nodes
Metastastatic stage
MX Distant metastasis cannot be assessed
M0 No evidence of metastasis
M1 Distant metastasis present
TNM stage Cumulative % Surviving*
1 Year 3 Year 5 Year
Occult TX, N0, M0
Stage 0 Tis, N0, M0
Stage Ia T1, N0, M0 90 71 61
Stage Ib T2, N0, M0 72 46 38
Stage IIa T1, N1, M0 84 42 37
Stage IIb T2, N1, M0 63 35 26
T3, N0, M0 54 30 21
Stage IIIa T3, N1, M0 58 12 9
T1-3, N2, M0 51 20 13
Stage IIIb T4, any N, M0 34 8 7
Any T, N3, M0 32 6 3
Stage IV Any T, any N, M1 17 2 <1
* Non-small cell lung cancer. Cumulative percent of patients surviving according to clinical staging criteria
Table 1. Tumour staging adapted from Mountain.[4]
endoscopical procedures for tissue procurement either from bronchial lesions or suspected 
metastases, imaging studies for localisation of abnormalities and sometimes invasive 
procedures to assess resectability of the tumour. The second route involves assessment of 
12
Chapter 1
the expected cardiopulmonary reserve after resection. This analysis includes laboratory tests, 
lung function tests, perfusion and ventilation tests, and a cardiovascular assessment. Judge-
ment of risk factors determines the operability of the patient. Staging of lung cancer patients 
not only provides important prognostic information with regard to survival, but also guides 
the decision-making process with regard to selection of optimal treatment.[5] Patients with 
stage IA, IB, IIA, IIB en selected cases with IIIA disease may benefit from surgical resection, 
in conjuncture with systemic treatment. Patients with stage IIIB, and IV almost never meet 
the criteria for surgery. 
A variety of diagnostic tests pertaining to each aspect of the TNM staging system is available 
to assist the clinician in achieving a definitive diagnosis and stage of lung cancer. At the same 
time, the impact and cost of staging lung cancer are augmenting due to the further increase 
of newly diagnosed NSCLC, and by the introduction of new diagnostic modalities. Adequate 
staging is important since it will prevent unnecessary major diagnostic procedures and 
operations. In Chapter 2 we evaluated the clinical practice, yield and costs of preoperative 
staging in patients with (suspected) non-small cell lung cancer in an academic and general 
hospital during a time period of two years (1993/1994). The importance of staging should 
be clear since unnecessary major diagnostic procedures and therapy like surgery should be 
avoided. Evidence- and consensus based guidelines for staging have been developed, which 
are adapted to new therapeutic and diagnostic developments from time to time.[6-8] One 
of the latter developments is the introduction of molecular imaging technology in oncology 
using 18F-fluorodeoxyglucose (18FDG) positron emission tomography (PET). 
18FDG PET, basic technique
PET is a physiologic imaging technique that uses radiopharmaceuticals produced by labelling 
metabolic markers such as glucose with the positron-emitting radionuclide fluorine-18 (a 
positron emitting isotope), which forms 18FDG. 18FDG preferentially accumulates within cells 
with a high rate of glycolysis and an increased cellular uptake of glucose, due to an increased 
expression of glucose transport proteins.[9,10] The radiopharmaceutical is typically imaged 
by coincidence detection of the two 511 KeV photons that are produced by annihilation 
of the emitted positrons. Dedicated or state-of-the-art PET cameras make use of Bismuth 
Germanium Oxide (BGO) multiple block detectors, which form a ring that surrounds the 
patient. By scanning several axial fields (usually between 15 and 25 cm) a whole-body image 
of the patient can be reconstructed.
The introduction of 18FDG PET as diagnostic tool in the investigation of suspected lesions 
would make it possible, with a single examination, to decide whether a lesion is malignant or 
benign, and to stage  a patient with suspected lung cancer.
18FDG PET and solitary pulmonary nodules 
The availability of various diagnostic algorithms [11,12] indicates that a standard strategy 
for clinical management of solitary pulmonary nodules (SPN) has not been defined. 
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Approximately one-third of pulmonary nodules are radiologically indeterminate and of these, 
one-third of the resected pulmonary nodules are benign.[13-17] With the increased interest 
in the use of low dose spiral computed tomography (CT) for early lung cancer detection, the 
number of coincidental SPNs will increase. Furthermore, repeated screening and technical 
improvements may result in the detection of very small lesions (2-10 mm in diameter) for 
which establishing a definitive diagnosis may become even more difficult. The published 
evidence on the accuracy of 18FDG PET in characterising SPNs (lesions smaller than 3 or 4 cm 
in diameter) consists of over 450 published cases with a mean sensitivity and specificity of 
18FDG PET for detecting malignancy were 93.9% and 77.8%, respectively.[18] Finally, sofar 
there is little information about 18FDG PET performance in nodules ≤ 10 mm, whereas this 
is an important theme since the introduction of CT screening for lung cancer. In Chapter 3 
we report on the diagnostic accuracy of 18FDG PET in radiologically indeterminate solitary 
pulmonary nodules (SPN) ≤10 mm.
Different management strategies circulate for patients with SPN. Decisions should be made 
adequate and timely to permit curative resection of malign lesions or to avoid surgery in 
benign lesions. A cost-effectiveness analysis proposed a diagnostic approach in SPN which 
strongly relied upon the result of clinical risk assessment.[19] This probability estimation 
was based on clinical and radiological parameters [20], but the underlying quantitative risk 
algorithm still needs to be externally validated. Further, whether and how addition of 18FDG 
PET results improves this prediction rule still needs to be established. These two issues are 
evaluated in chapter 4. 
Staging NSCLC
18FDG PET has been shown to provide useful information in staging of NSCLC. Several 
case series claimed 18FDG PET to be superior over conventional staging in determining 
hematogeneous and locoregional spread.[21-26] These findings suggest that 18FDG PET may 
both improve and simplify the staging process. Moreover, the idea of a single whole body 
18FDG PET to establish disease stage rather than a lot of procedures and tests is appealing. 
Most studies performed evaluate diagnostic accuracy or clinical outcome. To determine 
the proper role of 18FDG PET and to appreciate its incremental benefits, it should not be 
evaluated in isolation from other tests. In addition, improved test performance does not 
necessarily translate into meaningful changes in clinical treatment decisions; nor does altered 
treatment necessarily translate into improved patient outcomes. Thus, to fully assess a new 
diagnostic technology, the evaluation must not only assess test performance but also the 
impact of the test on decision making and clinical outcomes. A way to perform such studies 
is determining diagnostic and therapeutic plans before and after the application of 18FDG PET 
by means of questionnaires.[27,28] Chapter 5 describes patients presenting with a  clinical 
problem in NSCLC and the degree to which the result of the research (18FDG PET) affected 
the diagnostic understanding and management. This was studied by questionnaires gathering 
information on intended diagnostic plans and treatment without PET, actual therapy of choice 
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after PET and post hoc clinical assessment to grade the usefulness in diagnostic understanding 
and choice of therapy. 
Modelling
To fully assess a new diagnostic technology, the evaluation must assess test performance, 
the impact of the test on decision making and clinical outcomes, such as morbidity and 
mortality as well as the value of substitution and cost-effectiveness of a new diagnostic tool. 
Several strategies can be reconstructed to evaluate the value of 18FDG PET. An advantage of 
a modeling approach is the possibility to vary the level of substitution of PET in the diagnostic 
work-up process and its consequent impact on the costs. By using clinical data the number 
of assumptions can be limited. To answer the question of the position of 18FDG PET within 
the diagnostic procedures for NSCLC, several study designs can be considered: 18FDG PET on 
top of regular staging, 18FDG PET before invasive staging or 18FDG PET in front of the staging 
process. Chapter 6 shows a cost modelling approach of 18FDG PET in NSCLC. Consequently, 
these findings have been used in the design of a randomised trial. 
The question if 18FDG PET could reduce the number of unnecessary thoracotomies was 
addressed in the PLUS trial [29] where the addition of 18FDG PET before surgery (after 
conventional work-up) resulted in a prevention of unnecessary thoracotomies in one out 
of five patients. However it still remains to be determined whether the use of 18FDG PET 
could replace conventional work-up (value of substitution) and shorten the work-up period 
without losing accuracy. In Chapter 7 we describe our randomised controlled trial of PET 
immediately after first presentation of patients with (suspected) NSCLC compared to the 
traditional strategy in routine clinical setting.
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Abstract
Background: A study was undertaken to investigate the clinical practice, yield, and costs of preop-
erative staging in patients with suspected NSCLC and to obtain baseline data for prospective 
studies on the cost effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the 
management of these patients.
Methods: A retrospective study of the medical records of all patients with suspected NSCLC was 
performed during a 2 year interval (1993-1994) in an academic and a large community hospital.
Results: Three hundred and ninety five patients with suspected NSCLC were identified; 58 were 
deemed to be medically inoperable and 337 patients proceeded to the staging process. Staging 
required a mean (SD) of 5.1 (1.5) diagnostic tests per patient (excluding thoracotomy) carried 
out over a median period of 20 days (IQR 10-31). Many of the tests (including both invasive and 
non-invasive) were done because previous imaging tests had suggested metastases, and in most 
cases the results of initial tests proved to be false positive. After clinical staging, 168 patients 
were considered to be resectable (stage I/II), and 144 patients underwent surgery with curative 
intent. At surgery 33 patients (23% of those who underwent surgery) were found to have irre-
sectable lesions and 19 patients (13%) had a benign lesion. Surgery was also considered as futile 
in 22 patients (15%) who developed metastases or local recurrence within 12 months following 
radical surgery. Hospital admission was responsible for most of the costs. 
Conclusion: In many patients staging involved considerable effort in terms of the number of diag-
nostic tests, the duration of the staging period and the cost, with limited success in preventing 
futile surgery. Failures relate to the quality of diagnostic preparation at every level of the TNM 
staging system. 
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Introduction
The selection of candidates for appropriate treatment, particularly for curative surgery, is 
the key issue in staging patients with non-small cell lung cancer (NSCLC).[1] A battery of 
diagnostic tests pertaining to each aspect of the TNM (tumour node metastases) staging 
system is potentially available. On the other hand, there are societal concerns and economic 
restraints. The cost of staging lung cancer is increasing because of an increase in newly 
diagnosed cases of NSCLC. Not surprisingly, guidelines for staging have been developed 
which can be adapted to include new therapeutic and diagnostic developments.[2-4] In 
the past decade new diagnostic methods such as magnetic resonance imaging (MRI) and 
positron emission tomography (PET) have emerged, claiming a role in the staging process. 
[5] The initial step in assessment of such new technologies should be the evaluation of 
prevailing clinical practice and its residual inefficiency. [6] Evaluation of the prevailing clinical 
practice based simply on the estimated use of guidelines is less desirable since adherence to 
such guidelines is unpredictable.[7] Studying actual patient data may be more accurate than 
questionnaires [8] or medical audits [9]; it also avoids the potential selection bias of socially 
desirable answers and accounts better for heterogeneity. 
We have systematically investigated the manner, yield and costs of NSCLC staging as carried out in 
two major Dutch hospitals. In addition, this study provided baseline data for prospective studies on 
the cost effectiveness of PET using 18F-fluorodeoxyglucose (18FDG).[10]
Methods
The medical records of all patients with diagnosed or suspected NSCLC referred by their 
family physicians to the pulmonologists of the academic hospital VU University Medical 
Center, Amsterdam (VUMC) and the community hospital Medical Centre Alkmaar (MCA) 
between January 1993 and January 1995 were reviewed. Patients were identified by cross-
linking databases of the Dutch Cancer Registry, the Pathological Anatomical National Register 
(PALGA), local surgery records and the minutes from regular multidisciplinary rounds. 
The following information was extracted: demographic data, pathological data, the number 
and type of diagnostic investigations (excluding laboratory and lung function tests), the 
duration of the diagnostic process until definitive clinical TNM staging, postoperative 
TNM classification and follow up data. Imaging tests, punctures/biopsies (not requiring 
mediastinoscopy, thoracotomy, video assisted thoracoscopy, or rigid bronchoscopy) and 
flexible bronchoscopy were classified as non-invasive investigations. Surgical staging 
procedures (such as mediastinoscopy, video-assisted thoracoscopy) and rigid bronchoscopy 
were classified as invasive investigations.
19
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Surgery was considered futile in cases of benign lesions, T4 lesions, macroscopic 
mediastinal lymph node involvement, or pleural metastasis. In addition, patients in whom 
a pneumonectomy was necessary to perform a complete resection but whose poor lung 
function allowed for only a less extended resection (such as (bi-) lobectomy) were also 
considered to have undergone futile surgery. Finally the diagnosis of distant metastases or 
local relapse during the 12 months after surgery with curative intent were also regarded as 
futile surgery.
Cost methodology
A cost analysis was performed to assess the costs of the staging procedures in both hospitals, 
including that of surgical resection and the resulting number of hospital admission days. Costs 
of any additional treatment were not included. The total cost of the diagnostic strategies was 
obtained by multiplying the number procedures performed by their individual costs. Detailed 
price calculations were made in the two hospitals to estimate unit costs accurately. This 
included the costs of personnel, materials, equipment, and overheads.
Analysis of data
Statistical analyses were performed using Student’s t-test, Fischer’s exact test and the Mann- 
Whitney U test. 
Results
Three hundred and ninety five patients with suspected NSCLC were identified; 58 were 
medically inoperable because of severe comorbidity, leaving 337 patients (220 and 117 from 
the community hospital and university hospital, respectively) for further analysis; 271 (80.5%) 
were men, and the mean age was 64 years (range: 27-88). The age and sex distribution were 
comparable in the two institutions.
Staging procedures
Chest radiography and flexible bronchoscopy were performed in all patients. A CT scan of the 
chest was performed in 315 patients. In 17 patients metastatic disease was found prior to CT 
scanning. In one patient the chest lesion proved to be a metastasis of urothelial carcinoma 
and further diagnostic tests were directed in search of the primary tumour. Four patients 
refused a chest CT scan. Between the first visit and the final clinical stage classification 
patients underwent a mean (SD) of 5.1 (1.5) diagnostic tests, with the number in the 
academic hospital (5.5 (1.7)) being higher than in the general hospital (4.8 (1.5); p=0.001). 
However, there was no significant difference in the number of diagnostic tests between 
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patients considered operable and those deemed to be inoperable (5.0 (1.6) and 5.1 (1.6), 
respectively). 
Apart from chest (and upper abdomen) CT scans, investigations carried out to find distant 
metastases in decreasing order of frequency (Table 1) were: ultrasound and abdominal CT 
scan (48%), bone scan (36%) and CT/MRI of the brain (16%). Further diagnostic tests were 
necessary to evaluate suspicious lesions in 116 of the 337 patients (34%) which resulted 
in an additional 112 imaging procedures and 71 biopsies (excluding invasive mediastinal 
procedures). Bone scintigraphy accounted for 49% of the additional imaging tests. In 46% of 
the 68 biopsied patients from whom biopsy specimens were taken, suspicious lesion proved 
to be benign and thus false positive. Bone scanning had the highest proportion of inconclusive 
results (36%) as compared to CT scanning of the abdomen/brain (4%) and ultrasound (3%). 
Twenty two (49%) of the 45 patients with inconclusive bone scans underwent surgery with 
curative intent. 
Invasive procedures aimed at nodal and primary tumour staging were performed in 39% of all 
patients. In 65% of these investigations, no malignant tissue was sampled. Mediastinoscopy 
was performed more often in the community hospital (59/99 patients, 60%) than in the 
academic hospital (9/69, 13%). In the latter, mediastinoscopy was performed only in case of 
enlarged (>1 cm) lymph nodes on chest CT scanning. 
Overall, 50% (169/337) of the patients proved to be ineligible for surgery with curative intent 
as a result of clinical staging. 
Duration of staging and costs 
The frequency distribution of the duration required for clinical staging was positively skewed 
towards longer durations (Fig 1). In 50% of the patients the diagnostic work up lasted more 
than 3 weeks (median 20 days (IQR 10-31)) where IQR= the numerical difference between 
the 25th and 75th centiles. This was especially true for patients eventually deemed to be 
operable (median 25 days (IQR 16-34) v 14 days (IQR 8-26) for clinically inoperable patients, 
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Table 1. Staging procedures aiming at nodal or distant metastases
IMAGING
Chest CT (+ upper abdomen) 143  (99%) 172  (89%)
Ultrasound (abdomen) 57  (40%) 87  (45%)
Bone Scintigraphy 45  (31%) 79  (41%)
CT /MRI brain 13    (9%) 41  (21%)
CT abdomen 7    (5%) 15    (8%)
INVASIVE PROCEDURES
Mediastinoscopy 67  (47%) 41  (21%)
Other 40  (28%) 117  (61%)
p<0.001). The majority of patients were admitted to hospital for staging (academic hospital 
61%, community hospital 95%). The mean hospital stay duration was approximately 1 week 
(median 9 days (IQR 2-15) for operable patients, 8 days (IQR 3-14) for inoperable patients). 
Hospital stay for staging and for postoperative care accounted for the majority of the costs 
(Table 2). The median postoperative hospital stay was 11 days in the academic hospital (IQR 
9-16) compared with 15 days in the community hospital (IQR 12-17). Overall, the costs for 
staging were about one third that of the costs associated with thoracotomy. Higher costs 
were noted in the community hospital related to more hospital admissions for staging and 
the performance of more mediastinoscopies. Costs were similar in patients undergoing futile 
or non-futile surgery.
Surgery and follow-up
Planned thoracotomy was cancelled in 24/168 patients. In three the suspected lesion proved 
to be benign (sarcoidosis (n=2), pneumonia (n=1)), six refused thoracotomy, and the remainder 
were deemed to be medically unfit for surgery either because of co-morbidity (CVA (n=3), 
Table 2. Mean costs (euro) per patient (1 euro = DFL 2.20) 
VUMC MCA
Staging (euro) 1284 3064
Operated patients 2056 3180
No surgery 498 2990
Thoracotomy* 6113 9018
Figure 1. Time between first visit and finalising clinical stage
VUMC = VU University Medical Centre, Amsterdam; MCA = Medical Centre Alkmaar.
* including hospital stay for staging and postoperative care, respectively. 
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cardiac events (n=6)) or deterioration of performance status (n=6). The exact time interval 
between the finalisation of clinical staging and the occurrence of the event precluding the 
planned thoracotomy could not be extracted from the medical records. Overall, in operated 
patients the median time interval between the finalisation of clinical staging and thoracotomy 
was 7 days (IQR 0-17).  According to our criteria, surgery was futile in 74 of the remaining 144 
patients (51%, 95% CI 43 to 60%; Table 3). Intraoperative staging consisted of lymph node 
sampling in the community hospital and mediastinal lymph node dissection in the academic 
hospital. Twenty patients underwent exploratory thoracotomy due to T4 lesions. Of these two 
patients had brachial plexus involvement, seven had direct extension into the heart and/or 
main stem of the pulmonary artery, six had tumours invading mediastinal structures, and five 
patients could not tolerate the pneumonectomy which at surgery proved to be necessary to 
achieve a complete resection due to poor lung function. Eleven patients had gross mediastinal 
lymph node involvement which had not been detected during the preoperative work up. In 
two patients thoracotomy was also considered explorative due to pleural metastasis. There 
was no significant correlation between the time between clinical and intraoperative staging 
for patients in whom the tumour was irresectable (median 34 days, IQR 28-49) and those 
with resectable tumours (median 31 days, IQR 23-45). Nineteen patients proved to have 
benign lesions (nine hamartomas, seven reactive lesions, two fibrosic lesions, one cyst). 
Table . Yield of clinical staging
VUMC = VU University Medical Centre, Amsterdam; MCA = Medical Centre Alkmaar; *P<0.01; 
**P=0.001
MCA
(n=253)
VUMC
(n=142)
After 1st screening (n) 220 117
Clinically unresectable (III/IV) 121 48
Clinically resectable(I/II) 99 69
Thoracotomy 85 100% 59 100%
Benign 9 11% 10* 17%
Irresectable at surgery 10 12% 23 39%
Due to T stage 7 13*
N stage 3 8*
M stage 0 2
Recurrence after radical surgery in NSCLC 13 15% 7 12%
Site:     Local 0 1
Brain 2 1
Bone 4 0
Liver 1 0
Mediastinum 2 2
Other 4 3
Recurrence < 1yr after surgery in other malignancy 2 2% 0
Total futile surgery 34 40% 40** 68%
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Tumour histology other than NSCLC was found in seven patients (two metastases of other 
primary tumours, three carcinoid tumours, one SCLC, and one mesothelioma). Three patients 
had bronchoalveolar cell carcinoma. 
Within 12 months after apparently curative surgery 22 patients were found to have recurrent 
disease: symptomatic distant metastases in 14, lymph node metastases in four, local 
recurrence in one, and “clinically evident” relapse (as reported by the general practitioner) 
in three patients (Table 3). Preoperatively, 10 of the 14 patients with a distant relapse (71%) 
had undergone dissemination tests aimed at the affected organ. In the seven patients 
with tumour histology other than NSCLC, two patients with metastases of other primary 
tumours (colon, embryonic cell cancer) also proved to have metastases within 1 year after 
surgery.  The other five patients remained disease-free during the follow up period and were 
not therefore considered to have undergone futile surgery. Five of the 144 patients who 
underwent curative surgery died within 3 months, one patient died between 3-12 months 
without evidence of disease, and six patients were lost to follow-up. 
Of all the patients with NSCLC, 21% (95% CI 16 to 25%) were alive and clinically disease free 
at 12 months follow-up. This was not significantly different for the two hospitals (VUMC 
18% (95% CI 11 to 25%), MCA 23% (95% CI 17 to 28%).
Discussion
In this systematic retrospective study staging of patients with NSCLC proved to be an 
intensive and often protracted effort with a disappointingly high proportion of futile 
thoracotomies. However, this failure rate is comparable to that reported by others.[11] VUMC 
is a tertiary referral centre for thoracic oncology so more patients with advanced tumours 
were considered for resection at this hospital. Unlike MCA (a community hospital), VUMC 
has a policy to staging central T3 and T4 lesions intraoperatively. 
Even though the clinicians attempts to minimise the delay due to staging were successful 
in many patients, a considerable subset went through a more protracted process. Tumour 
negative test results were abundant, which is obviously useful if they alter the pretest 
perception of curability. Unfortunately, most procedures were simply the sequel of earlier 
imaging tests suggesting metastases. This reflects specificity problems of these techniques 
and, in the case of mediastinoscopy, also the limited sensitivity of chest CT scans. It is possible 
that clinicians may have ordered dissemination tests at the same time as the initial work up 
tests in an effort to maintain momentum in the diagnostic process. For example it is unclear 
what the impact of chest CT scan might have been in patients already diagnosed with brain 
metastases on MRI. However, in 77% of the cases dissemination tests were performed in 
compliance with the 1994 guidelines of Goldstraw et al.[3] (69% VUMC, 81% MCA). More 
imaging tests than are indicated by this guideline were performed in 15% (26% VUMC, 9% 
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MCA) and fewer than recommended were performed in 8% (4 % VUMC, 10% MCA). With 
respect to mediastinal staging procedures, practices at both hospitals were compatible with 
prevailing guidelines.[3,4] Even though differences in peroperative and postoperative failure 
patterns between hospitals appeared to reflect the differences in staging practice, the final 
result of diagnosis and treatment in terms of disease free 1 year survival between the two 
hospitals was identical.
From an economic perspective, the cost of the diagnostic tests themselves was only part of 
the problem. In the Netherlands costs mainly result from hospital admission for the staging 
procedures rather than from the tests themselves. This practice of hospitalisation is mainly 
intended to keep the staging process within acceptable time limits for patients. However, 
surveys carried out before this study (unpublished data) have shown that clinicians were 
under the impression that staging lasted a maximum of 2 weeks. The measurement of the 
actual time frame in this study confirms that questionnaires probably would have provided 
incorrect data in this respect. 
Whole body PET allows for staging of the entire patient with a single scan, with the exception 
of assessment of local tumour infiltration and brain metastases. Whether its application in 
daily clinical practice will simplify the staging process and improve the final selection of 
patients for appropriate treatment is currently under study in clinical trials. There is evidence 
to suggest that mediastinoscopy can be omitted in cases with a negative PET scan of the 
mediastinum (with the exception of central tumours).[12,13]
In summary, many patients with suspected NSCLC undergo extensive investigations for clinical 
staging with ultimately disappointing results which apply to every level of the TNM system. 
Whether the current multistep process can be improved in terms of cost effectiveness by 
comprehensive techniques such as PET scanning remains to be shown in clinical trials. This 
study provides important baseline data for such trials.
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Abstract
Background: Solitary pulmonary nodule (SPN, intraparenchymal lung mass < 3 cm) is often a 
diagnostic challenge. This study was performed  to evaluate the diagnostic accuracy of 18F-fluo-
rodeoxyglucose positron emission tomography (18FDG PET) in radiologically indeterminate SPN 
≤10 mm on spiral CT. 
Methods: Between August 1997 and March 2001, we identified all patients with radiologically 
indeterminate SPNs ≤ 10 mm who were referred for 18FDG PET imaging to the VU University 
Medical Centre. All PET scans were retrospectively reviewed by an experienced nuclear medicine 
physician. PET was considered positive in cases with at least moderately enhanced focal uptake, 
and otherwise as negative. Lesions were considered benign on the basis of histology, no growth 
during 1.5 yrs or disappearance within at least 6 months. 
Results: Thirty-five patients with 36 SPN ≤ 10 mm in diameter at clinical presentation were identified 
(one patient had two metachronous lesions). In 13 of 14 malignant nodules and in two of 22 
benign nodules, diagnosis was confirmed by histology. Prevalence of malignancy was 39%. PET 
imaging correctly identified 30 of 36 small lesions. One lesion proved to be false negative at PET 
(CT:10 mm), and in five lesions, PET scans proved to be false positive. Specificity was 77% (17/22; 
95% CI: 0.55-0.92), sensitivity 93% (13/14; 95% CI: 0.66-1.0), positive predictive value 72% 
(13/18; 95% CI: 0.46-0.90) and negative predictive value 94% (17/18; 95% CI: 0.73-1.0). 
Conclusion: This retrospective study suggests that 18FDG PET imaging could be a useful tool in 
differentiating benign from malignant SPNs ≤ 10 mm in diameter at clinical presentation. Such 
results may help to design larger prospective trials with structured clinical work-up.
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Introduction
The availability of various diagnostic algorithms [1-3] indicates that standard clinical strategy 
for solitary pulmonary nodules (SPN) has not been defined. Approximately half of the patients 
undergoing surgical biopsy of an indeterminate lung nodule proved to have benign disease.[4-
7] Among indeterminate lesions smaller than 10 mm, the prevalence of a benign lesion could 
be even higher than among those lesions > 10 mm.[8]
With the increased interest in the use of low-dose spiral computed tomography (CT) for early 
lung cancer detection, the number of coincidental SPNs will increase. Furthermore, repeated 
screening and technical improvements may result in the detection of very small lesions (2-10 
mm in diameter) for which it is even more difficult to establish a definitive diagnosis. The 
yield of flexible fibre-optic bronchoscopy (20-62%) is directly related to the visibility and the 
size of the lesions [9,10]; similarly, the accuracy of transthoracic needle biopsy depends on 
the size of the lesion and  ranges from 74 to 96%.[11,12] The chance of a non-diagnostic 
result is significant in lesions smaller than 2 cm, and the risk of a pneumothorax is substantial 
(3.1-41.7% [13]). Since a wait-and-see policy carries potentially adverse effects on outcome, 
there is a demand for accurate non-invasive tests to prevent surgical interventions for benign 
lesions. 
It is important to identify malignant nodules as early as possible because 5-year survival in 
patients with resected non-small cell lung cancer (NSCLC) stage IA that has been resected 
can be 80%.[14,15] In patients with proven or strongly suspected NSCLC, adding 18F-
fluorodeoxyglucose positron emission tomography (18FDG PET) to the diagnostic work-up 
improves the selection of surgical candidates [16], but its role in radiologically indeterminate 
SPNs is less well established.[17] The published evidence on the accuracy of 18FDG PET in 
characterising SPNs consists of over 1,400 published cases [18], in which the mean sensitivity 
and specificity were 96% and 73.5%, respectively. However, it was noted that different 
criteria are used to classify the PET results. Standardised uptake values (SUVs) may provide 
numerical thresholds to differentiate malignant and benign lesions, but visual assessment 
may be at least as sufficient [19] and is highly reproducible.[20] However, in small lesions it is 
not yet clear which level of tracer uptake in the lesion relative to background activity results 
in both the best sensitivity and specificity. The lesion contrast on 18FDG PET will decrease 
in lesions with a diameter smaller than twice the spatial resolution of the system, which is 
typically 5-7 mm for a state-of-the-art BGO full ring scanner. 
The aim of the present study was to assess the optimal operating characteristics of visual 
assessment, and to provide an initial estimate of the diagnostic accuracy of 18FDG PET in 
SPNs with a maximum diameter of 10 mm.
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Materials and methods
Between August 1997 and March 2001 all patients with an SPN who underwent PET imaging 
were retrospectively identified from the database of the PET centre at the VU University 
Medical Centre (VUmc). Patients are registered in the database of the clinical PET centre 
according the American College of Radiology Index for Radiological Diagnoses. Two hundred 
and twenty-two patients with pulmonary lesions ≤ 30 mm were identified using the above 
mentioned search strategy. In 199 of these patients a chest CT was obtainable. Thirty-four 
patients were not included because of a radiographically occult lung cancer or multiple lung 
lesions. In two patients no definitive diagnosis (malignant or benign) could be obtained by 
pathology or follow-up due to early death. All patients with an SPN ≤ 10 mm in diameter 
on CT were eligible for the present study. An independent experienced radiologist (R.P.G.) 
reviewed all CT scans, blinded for clinical pretest data, 18FDG PET result and outcome. If the 
SPN was ≤ 10 mm in diameter and without typically benign calcifications, it was classified as 
indeterminate and included in the study. Prior malignancy and diabetes were not exclusion 
criteria. 
CT and 18FDG PET
We reviewed chest CT scans with the shortest interval between PET and CT. Spiral CT was 
performed with axial slice thickness of 10 mm; in one patient axial slice thickness of CT was 
4 mm and in another patient, 5 mm. In three patients high-resolution CT (1 mm axial slice 
thickness) was performed. Intravenous contrast was used in some but not all institutions. 
Images were analysed with both a mediastinal and a pulmonary parenchymal setting. The 
parenchymal setting was used to measure lesion diameter. 
PET was performed with a dedicated full ring BGO scanner (ECAT EXACT HR+, CTI/Siemens). 
Emission scans, were acquired in 2D mode (5-7 min/bed position), approximately 60 minutes 
after intravenous injection of 370 MBq (10mCi) 18FDG. Patients were asked to fast for at 
least 6 h prior to PET. All scans were corrected for decay, scatter and randoms. Scans were 
reconstructed using ordered subset expectation maximisation (OSEM) with two iterations 
and 16 subsets, followed by post-smoothing of the reconstructed image using a Hanning 0.5 
filter resulting in a transaxial spatial resolution of 7 mm at full-width half-maximum.
Data analysis
A visual analysis of 18FDG PET scan was performed by an experienced nuclear medicine 
physician who was blinded to patient outcome. In a first session, he was blinded to all clinical 
information other than the nature of the study. In the second session, localisation and lesion 
diameter were also provided. To simulate usual reporting practice, 18FDG PET results using 
pre-test data were used for analysis. Intensity of FDG uptake of pulmonary lesions was 
visually associated with mediastinal background activity [21] and scored using a four-point 
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scale (absent, faint, moderate or intense). Final classification was based on histopathological 
findings or clinical and radiological follow-up. Radiological follow-up typically consisted of 
repeat CT scan of the thorax. Lesions were considered malignant on the basis of pathology 
or growth at radiological follow-up. Lesions were classified as benign on the basis of 
pathological findings, disappearance of the lesion at radiological follow-up, or absence of 
growth within an observation period of at least 1.5 years. 
Probability of malignancy
If applicable, we assessed the pre-PET probability of malignancy, using the model according 
to Swensen [22], which applies to patients with indeterminate SPN without cancer within the 
past 5 years or a history of primary lung cancer.
This clinical prediction model for malignancy in SPN expresses the probability of malignancy 
as a function of six variables, three clinical (age, current or former cigarette smoker, history 
of cancer more than 5 years ago) and three radiographic (diameter, spiculation and location 
in upper lobe). 
Clinical impact of 18FDG PET
Between July 1997 and July 2001, the impact of 18FDG PET on diagnostic understanding and 
management was prospectively assessed using questionnaires. These forms were completed 
by the referring physicians and included information on the intended treatment plan prior to 
18FDG PET, the actual therapy choice after 18FDG PET, and a post hoc clinical assessment of 
the impact of 18FDG PET on diagnostic understanding and management.[23,24] In the first 
questionnaire, information was requested regarding the histological diagnosis (if known), 
a definition of the current diagnostic problem, a differential diagnostic consideration, the 
results of diagnostic tests already performed and any planned diagnostic tests. In addition, 
the referring physician was requested to outline the intended patient management plan 
if 18FDG PET scanning was not available. The second questionnaire requested information 
regarding the working diagnosis and planned treatment after 18FDG PET scanning in addition 
to any diagnostic tests that had been ordered as a direct consequence of the 18FDG PET scan 
result. In the final questionnaire, the referring physician was requested to convey the final 
diagnosis and to rate the overall usefulness of 18FDG PET separately in terms of diagnostic 
understanding and therapy choice  according to the method of Wittenberg et al.[24] This 
method involves using a five-point ordinal scale, with higher scores representing increasing 
positive impact. 
Statistical analysis 
Sensitivity, specificity, accuracy, positive predictive value and negative predictive value of 
18FDG PET were determined. For each parameter the 95% confidence intervals (95% CI) were 
calculated using confidence interval analysis version 1.0. Receiver operating characteristic 
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(ROC) curves for clinical prediction model and PET were derived using SPSS 10.0 and were 
evaluated by comparing the areas under the ROC curve.
Table 1. Clinical and histological findings
FU, Follow-up; LLL, left lower lung; LUL, left upper lung; RLL, right lower lung; RML, right middle lung; 
RUL, right upper lung
Lesion Size on CT 
(mm)
History of 
cancer < or > 
5 years
Location Intensity of 
FDG uptake
Pathology/
FU (growth/no growth/ 
disappearance)
Time between 
PET and CT
(days)
1 3 RLL Moderate Lymphoma 29
2 5 Yes<5y RUL Moderate NSCLC 0
3 5 Yes<5y LLL Intense Lymphoma 71
4 5 RML Absent FU (disappearance) 42
5 5 RUL Faint FU (no growth) 25
6 7 LUL Moderate Sarcoidosis 3
7 7 RML Absent FU (disappearance) 8
8 8 LUL Intense NSCLC 33
9 10 Yes<5y LUL Intense Metastasis 55
10 10 RLL Moderate NSCLC 0
11 10 LUL Faint Carcinoid 0
12 10 Yes >5y RUL Intense NSCLC 99
13 10 LUL Moderate NSCLC 93
14 10 RUL Intense Carcinoid 55
15 10 LLL Moderate SCLC 27
16 10 LLL Intense NSCLC 24
17 10 RUL Intense NSCLC 73
18 10 RUL Intense Fibrosis/granulomatosis 16
19 10 RLL Faint FU (disappearance) 11
20 10 RUL Intense FU (no growth) 20
21 10 LUL Absent FU (no growth) 14
22 10 RUL Absent FU (no growth) 29
23 10 Yes >5y LUL Absent FU (no growth) 40
24 10 LUL Moderate FU (growth) 65
25 10 RML Moderate FU (disappearance) 45
26 10 RUL Faint FU (no growth) 6
27 10 Yes<5y RML Absent FU (no growth) 66
28 10 LUL Moderate FU (disappearance) 17
29 10 RML Absent FU  (no growth) 16
30 10 RML Absent FU (disappearance) 36
31 10 LUL Absent FU (no growth) 62
32 10 RML Absent FU (disappearance) 42
33 10 LUL Absent FU (no growth) 60
34 10 LLL Absent FU (no growth) 41
35 10 LUL Absent FU (disappearance) 71
36 10 RUL Absent FU (disappearance) 2
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Results
In 35 patients (36 pulmonary nodules) the pulmonary nodule was ≤ 10 mm in diameter (one 
patient had two separate lesions). Referring physicians were pulmonologists from university 
(n=13) and community (n=22) hospitals. Fifty-seven percent of the patients were female. 
Patients’ mean age was 61 years (SD 10), with 13 pack years of smoking (median; range 0-55). 
Six patients had a history of prior malignancy. Clinical and histological data are listed in Table 
1. In all patients SPN was located peripherally. In the 32 cases to which the model of Swensen 
was applicable (no prior cancer within 5 yrs), the mean pretest probability of malignancy was 
15% (SD 12). The distribution of SPNs was: left lung 16, upper lobes 22, lower lobes 7 and 
middle lobes 7. The mean size at CT was 9 mm (range 3-10), and 28 measured 10 mm. 
Fourteen of 36 nodules proved to be malignant (prevalence 39%). The final diagnosis was 
confirmed by histology in 13/14 malignant (NSCLC 7, lymphoma 2, SCLC 1, carcinoid 2, 
metastasis 1) and in two of 22 benign nodules (granuloma, sarcoidosis). In the remaining 
lesions, the median duration of radiological follow-up was 293 days for lesions that 
disappeared [IQR 119-429 (IQR, inter quartile range, i.e. the numerical difference between 
the 25th and 75th centiles), n=10], and 726 days in lesions without growth (IQR 564-1038, 
n=11). Radiological progression was found in a single patient who was inoperable due to poor 
pulmonary function. In eight patients CT was performed after 18FDG PET. In the remaining 
28 patients median time between CT and 18FDG PET scan was 35 days (IQR 16-59). In ten 
patients, thoracotomy followed PET after a median of 57 days (IQR 27-119).
18FDG PET results 
18FDG PET readings with and without knowledge of localisation and size were identical in 
all but one case, in which the lesion was only recognised at 18FDG PET after this additional 
information had been made available. This lesion was then classified as a positive 18FDG PET 
result (moderate uptake). For further analysis, we used the readings that included knowledge 
of size and localisation since this situation closely resembles clinical practice. ROC analysis 
revealed that using a at least moderately enhanced uptake as a cut-off for 18FDG PET test 
positivity (i.e. suspicious for malignancy) yielded a sensitivity of 93% (13/14; 95% CI: 0.66-
1.0) and a specificity of 77% (17/22; 95% CI: 0.55-0.92) (Fig 1). Using this threshold, 18FDG 
PET imaging correctly identified 30 of 36 SPNs; it was false negative in a 10-mm lesion which 
proved to be carcinoid (primary) at surgery. This patient had a fasting state blood glucose of 
6 mmol/l. The referring physician decided to proceed to thoracotomy to obtain histological 
diagnosis of the SPN. 18FDG PET was false positive in five cases: two proved to be fibrosis and 
sarcoidosis at pathology, in another two cases the lesion disappeared and in the final case 
the lesion was stable at prolonged follow-up. 
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Clinical impact
In 28 of 36 18FDG PET scans information was available on the impact on diagnostic 
understanding and management. Patients included in ongoing prospective studies (n=6) 
and patients with incomplete forms from referring physician (n=2) were not included in the 
assessment of this impact (i.e. the response rate was 93%). 18FDG PET had a positive influence 
on diagnostic understanding in 22 of 28 (79%) cases. According to referring physicians 18FDG 
PET resulted in beneficial change of therapy in 16 of 28 (57%), most importantly obviating 
the need for surgery in 12 of 16 patients. In three other patients, surgery was substituted for 
observation. A management change within surgery occurred in one patient. 
Discussion
In this retrospective study, a simple visual assessment of 18FDG PET scans adequately classified 
radiologically indeterminate SPNs ≤10 mm in diameter at clinical presentation. In fact, our 
Figure 1. ROC curve for 18FDG PET results. 
Sensitivity (true positive rate) vs 1-specificity 
(false positive rate)
Table 2. Predicted negative and positive predictive values as a function of prevalence of malignancy, 
using test performance characteristics of the present study (i.e. sensitivity 93%, specificity 77%).
NPV, Negative predictive value; PPV, positive predictive value
NPV PPV
Prevalence 10% 0.99 0.31
Prevalence 39%    0.95 0.72
Prevalence 55% 0.90 0.83
Prevalence 90% 0.55 0.97
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estimates of accuracy fit well into the summary ROC curve provided by Gould et al [18], 
which was predominantly based on studies of larger SPNs. 
A visual analysis of 18FDG PET scan was performed because it has been shown that SUV 
methodology and implementation is less straightforward than was often assumed. There is still 
debate about the appropriate normalisations to be used, and more recently it was demonstrated 
that  results of SUVs strongly depend on image reconstruction methodology.[25] Moreover, a 
recent meta-analysis failed to show that semi-quantitative image interpretation improves the 
accuracy of 18FDG PET.[18] Finally, the lack of standardisation in the current PET literature and 
practice strongly compromises the theoretical advantage of “objective” measurements. 
In practice, management of SPNs is based on the perceived probability of malignancy 
(depending on radiological and clinical variables). An important reason for variation in 
management lies in discrepancies between clinicians in estimating the probability of 
malignancy (especially in the case of intermediate probabilities).[26] To reduce the effect of 
such heterogeneity (i.e. inclusion of lesions obviously malignant or benign at CT scanning) 
in this study, an experienced radiologist identified the patients with truly radiologically 
indeterminate SPNs. 
Every imaging technique has a detection limit. In nuclear medicine technology, the dominant 
factor of lesion visualisation is the relative tracer uptake versus the background. For FDG-avid 
tumours like melanoma, it has been shown that accuracy clearly declines below the spatial 
resolution of the present generation of scanners.[27] Until respiratory gating techniques are 
generally available, the 18FDG signal arising from peripheral lung lesions will be smeared due 
to the superficial breathing during acquisition, which typically lasts for 5 minutes with the 
present generation of scanners. Within the lung, the background level of 18FDG activity varies, 
according to both ventrodorsal and craniocaudal gradients, being lowest in the upper and 
anterior lungs.[28] Finally, just above the diaphragm, scatter from photons arising from the liver 
may adversely affect both image quality and lesion detectability. In our study, these factors 
did not affect the accuracy of PET, but the proportion of lower lobe lesions was relatively 
small (7/36). Based on the experience with other tumours, we would expect that the negative 
predictive value of currently available PET camera’s for peripheral lung lesions < 5-7 mm may be 
insufficient for clinical implementation. 
Thirty-nine percent of the SPNs in our study was malignant. This is clearly lower than the 
reported prevalence in many other studies (ranging from 55-88% [18]), but clearly higher than 
the prevalence of malignancy in SPNs detected in lung cancer screening programs (range 7%-
24% [29,30]). This suggests that the negative predictive value of 94% observed in the present 
study may not be applicable in such conditions (Table 2). Similarly, depending on the specific 
clinical situation, one might consider other thresholds for test positivity with 18FDG PET. 
A limitation of the retrospective nature of the present study is the median time lapse of 35 
days between spiral CT and 18FDG PET. Presuming a high tumour doubling time of 30 days, 
exponential growth and a spherical nodule, the expected diameter of a malignant pulmonary 
nodule with an initial diameter of 5 mm would be 6.2 mm after 28 days, and 12.4 mm for 
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lesions of initially 10 mm diameter.[31] However, retrospective calculations (starting with 
size at pathology) for our patients using a high tumor doubling time of 30 days, resulted in 
tumour sizes within the 10 mm limit at time of 18FDG PET. 
Conclusion
In summary, together with the clinically perceived yield of adding 18FDG PET to standard 
probability estimation, our accuracy data suggest that studies are warranted on the accuracy 
and clinical utility of 18FDG PET in small indeterminate SPNs detected at CT. Ultimately, 
the focus of such investigations will have to extend beyond accuracy to include analysis of 
relevant patient outcome measures and costs. 
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Abstract
Background: The added value of 18FDG PET as a function of pre-test risk assessment in indetermi-
nate pulmonary nodules is still unclear. 
Objective: To obtain an external validation of the prediction model according to Swensen and col-
leagues, and to quantify the potential added value of 18FDG PET as a function of its operating 
characteristics in relation to this prediction model, in a population of patients with radiologically 
indeterminate pulmonary nodules. 
Methods: Between August 1997 and March 2001, all patients with an indeterminate solitary pul-
monary nodule referred for 18FDG PET were retrospectively identified from the database of the 
PET centre at the VUmc. 
Results: One hundred six patients were eligible, and 61 (57%) proved to have malignant nodules. 
The goodness-of-fit statistic for the model (according to Swensen) indicated that the observed 
proportion of malignancies did not differ from the predicted proportion (p=0.46). 18FDG PET 
results classified using the 4-point intensity scale reading yielded an area under the evaluated 
receiver operating characteristic curve of 0.88 (95% CI 0.77-0.91). The estimated difference of 
0.095 (95% CI: -0.003-0.193) between the 18FDG PET results classified using the 4-point inten-
sity scale reading and the area under the curve (AUC) from the Swensen prediction was not 
significant (p=0.058). 18FDG PET added to the predicted probability calculated by the Swensen 
model improves the AUC by 13.6 % (95% CI: 6-21; p=0.0003).
Conclusion: The clinical prediction model of Swensen et al. [1] was proven to have external validity. 
However, especially in the lower range of its estimates, the model may underestimate the actual 
probability of malignancy. The combination of visually read 18FDG PET scans and pretest factors 
appears to yield the best accuracy. 
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Introduction
Radiologically indeterminate solitary pulmonary nodules (SPN) are a diagnostic challenge in 
pulmonary medicine. Currently, most SPN’s are discovered by plain chest films. With the 
introduction of computed tomography (CT) screening for lung cancer, the number of SPN 
will strongly increase. Unfortunately, after a full noninvasive evaluation the diagnosis may still 
be unclear.
One comprehensive cost-effectiveness analysis proposed a diagnostic approach which 
strongly relied upon clinical risk assessment.[2] This probability estimation was based on 
clinical as well as radiological parameters, and has been developed and preliminarily validated 
in a United States population.[1] The cost-effectiveness analysis included the potential role of 
18F-fluorodeoxyglucose (18FDG) positron emission tomography (PET) scanning. However, the 
criteria for judging test results with 18FDG PET are heterogeneous [3], and standardisation 
would be desirable. The added value of 18FDG PET as a function of pre-test risk assessment 
still needs to be established. 
The aims of the present study were two-fold: first, to obtain an external validation of the 
prediction model; and second, to quantify the potential added value of  18FDG PET as a 
function of its operating characteristics in relation to this prediction model in a population of 
patients with radiologically indeterminate pulmonary nodules. 
Methods 
Between August 1997 and March 2001, all patients with an indeterminate SPN, detected 
during normally clinical work in both university and community hospital setting, referred 
for 18FDG PET were retrospectively identified from the database of the PET centre at 
the VU University Medical Centre (VUmc). In our database, characteristics of all patients 
are registered using a modified version of the American College of Radiology Index for 
Radiological Diagnoses.
An independent experienced radiologist (RPG), who was blinded to clinical pretest data, 
18FDG PET results and outcome reviewed all CT scans. Patients were eligible for the study if 
the SPN was ≤ 30 mm in diameter on CT and without typically benign calcifications. Patients 
with prior malignancies within the past 5 years before 18FDG PET scanning, unknown history 
of malignancy or without a definitive clinical diagnosis, or patients lost to follow-up were not 
eligible. 
All medical records were reviewed to obtain the following data: age, gender, smoking status 
(current or former cigarette smoker, number of pack-years), history of malignancy (date and 
kind of malignancy), pathology (conclusion and date) and last date of clinical and radiological 
follow-up (including: disappearance of the SPN or decreased size, no growth and growth).
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Imaging CT
Spiral CT scanning was performed with axial slice thickness of 10 mm in 96 patients, 5 mm in 2 
patients and 4 mm in another patient. In seven patients a high-resolution CT (1 mm axial slice 
thickness) was performed. Intravenous contrast was used at some but not all institutions.
Images were analysed with mediastinal as well as pulmonary parenchymal settings. The 
SPN diameter (ie, the mean of diameters in the transverse plane in millimeters), its location 
(ie, upper lobe or elsewhere) and the presence of spiculae (ie, < 50% or ≥ 50% of the 
circumference) were recorded. 
Imaging 18FDG PET
18FDG PET was performed with a dedicated full-ring BGO scanner (ECAT EXACT HR+, CTI/
Siemens;Knoxville, TN). Emission scans, were acquired in the two dimensional mode (5-7 
min/bed position), approximately 60 minutes after intravenous injection of 370 MBq of 
18FDG. Patients were asked to fast for at least 6 hours prior to undergoing the PET scan. All 
scans were corrected for decay, scatter and randoms, and were reconstructed using ordered 
subset expectation maximisation (OSEM) with 2 iterations and 16 subsets followed by post 
smoothing of the reconstructed image using a Hanning 0.5 filter, resulting in a transaxial 
spatial resolution of 7 mm at full-width half-maximum.
One experienced nuclear medicine physician (EFC) reviewed all 18FDG PET scans. A visual analysis 
of 18FDG PET scan was performed blinded to patient outcome. To simulate usual reporting 
practice, localisation, and diameter of the lesion were provided. The intensity of 18FDG uptake 
was scored using a 4-point scale (0, absent; 1, faint; 2, moderate; or 3, intense). Inter-observer 
variation of this classification system was assessed by asking seven relatively inexperienced 
nuclear medicine physicians, who were blinded for all clinical and radiological information other 
than “SPN,” to score a randomly chosen subset (25% of the present material). Semiquantitative 
analysis was performed using tumour normal lung tissue ratio (T/N).
Diagnosis
Final classification was based on histopathological findings or clinical and radiological follow-
up. Time of follow-up was defined as time between 18FDG PET imaging and histological 
diagnosis or date of last radiological follow-up. Radiological follow-up typically consisted 
of repeat chest CT scans. Lesions were classified as benign in case of benign pathological 
findings, disappearance of the lesion at radiological follow-up, or no change in size within 
an observation period of at least 1 year. Lesions were considered malignant on the basis of 
pathology or growth at radiological follow-up.
Clinical prediction model according to Swensen [1] 
This model expresses the probability of malignancy as a function of 3 clinical and 3 
radiographic variables as follows: 
probability of malignancy = 1 / (1 + e-x)
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where x = -6.8272 + 0.0391{age} + 0.7917 {cigarettes} + 1.3388 {cancer} + 0.1274 
{diameter} + 1.0407 {spiculation} + 0.7838 {upper}; e is the base of natural logarithms; 
age is the patient’s age (years); cigarettes is 1 if the patient is a current or former smoker 
(otherwise, 0); cancer is 1 if the patient has a history of extrathoracic cancer diagnosed > 5 
years ago (otherwise, 0); diameter is the diameter of the SPN in millimeters; spiculation is 1 
if the edge of the SPN has spiculae (otherwise is 0), and upper is 1 if the SPN is located in 
an upper lobe (otherwise is 0). The model was validated for an American population with a 
26.4% prevalence of malignancy.
Statistical analysis
The model fit was assessed by a goodness-of-fit for binary logistic regression, [4] as 
implemented by Harrell et al,[5] where high p values indicate a well-calibrated model. The 
predictive ability was expressed by various statistics, among others the area under the receiver 
operating characteristics (ROC) curve. The area under the curves (AUCs) were compared using 
the method described by DeLong et al [6] and logistic regression models were compared 
using Akaike’s information criterion (AIC). First the accuracy of the prediction model of 
Swensen et al [1] was determined on the study population. Second, the characteristics of 
18FDG PET, as a univariate test with 4 categories, were calculated. Finally, the added value 
of 18FDG PET to the Swensen model [1] was explored. A nomogram was constructed using 
the pretest probability of the model of Swensen et al combined with the value of 18FDG PET. 
Interobserver variation of 18FDG PET classification was analysed with intraclass correlation 
coefficients. Extensive use was made of programs developed (S-plus, version 6.2; Insightful; 
Seattle,WA)  by Harrell et al.[5]
Results 
In total, 106 eligible patients were identified of whom 61 (57.5%) proved to have malignant 
nodules. Referring physicians were pulmonologists from university (n=25) and community 
(n=81) hospitals. Fifty-eight percent of the patients were male and their mean age was 64 
years (range 32-85) (Table 1). The diagnosis of malignancy was based on histopathological 
results in 55 patients and on radiological growth of the lesion in 6 patients. The diagnosis 
of a benign lesion was based on the stabilisation or spontaneous decrease in size of the 
lesion at follow-up CT in 40 patients and on the histopathological result in 5 patients. In 
patients with radiological stable SPNs (n=23) the median follow-up was 646 days (interquartil 
range 413-925 days), and only 6 had a follow-up < 365 days (with a minimum of 203 days) 
versus 205 days (interquartile range  143-398 days) in the 17 patients with shrinking or 
disappearing lesions. Interquartile range, i.e. the numerical difference between the 25th and 
75th centiles.
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Malignant (n=61) Benign (n=45)
Mean age, years (sd) 66 (10) 60 (13)
Male/female 35/26 27/18
Current or former smoker 53 26
Cancer > 5 yrs ago 9 1
Spicula ³ 50% 34 8
Location 
Upper lobe 40 30
Elsewhere 21 15
diameter (mm)
≤ 10 11 22
11-20 26 16
21-30 24 7
18FDG PET uptake
Absent 1 26
Faint 1 6
Moderate 16 7
Intense 43 6
Table 1. Baseline demographic data (n=106): 
Figure 1. Validation of the clinical prediction model of Swensen in 106 patients with SPNs
Computed indexes and statistics: Dxy: Somers Dxy rank correlation between actual and predicted 
probability; C: ROC area; R2: Nagelkerke-Cox-Snell-Maddala-Magee R-squared index; D: discrimination 
index (logistic model LR-chi-square-1/n; U: unreliability index (chi-square with 2d.f. for testing unreliability); 
Q: quality index Q, Brier score (average squared difference between actual and predicted probability); 
Emax: maximum absolute difference in predicted and calibrated probabilities.
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Validation of the Swensen model [1] 
The goodness-of-fit statistic for the model indicated that the observed proportion of 
malignancies did not differ from the predicted proportion (p=0.46). The probability of 
malignancy was calculated using the complete model (eg variables with specified coefficients) 
of Swensen. The ROC-AUC was 0.79 (95% confidence interval [CI]: 0.70-0.87). A calibration 
curve of the model including a series of statistics is shown in Figure 1. 
Operating characteristics of 18FDG PET
18FDG PET results classified using the 4-point intensity scale reading (Figure 2) yielded an ROC- 
AUC value of 0.88 (95% CI 0.77-0.91). A tumour normal tissue (T/N) ratio on these data showed 
identical AUC-ROC values (AUC 0.87 (95%CI 0.80-0.94)). All other analyses were performed 
using the 4-point intensity scale reading. The estimated difference of 0.095 (95% CI: -0.003-
0.193) with the AUC from prediction of the Swensen et al [1] was not significant at p=0.058. 
Classifying the 6.6% proportion (n=7) with faintly enhanced 18FDG uptake as negative, yielded 
a sensitivity of 96.7% (95% CI: 87.6-99.4; 59/61), a specificity of 71.1% (95% CI: 55.5-83.2; 
32/45) and an accuracy of 86% (95% CI: 77.4-91.6). Two nodules without enhanced 18FDG 
uptake proved to be papillary adenocarcinoma (diameter, 30 mm) and carcinoid (diameter, 10 
mm) at pathology. Thirteen nodules with increased 18FDG uptake were classified as benign, 
with histological diagnoses of fibrosis (one patient), hematoma (two patients), reactive 
granulomatosis (two patients), radiological regression (seven patients) or no growth (one 
patient). Inter-observer correlation of visual analysis of 18FDG PET using intensity scales was 
0.87 (95% CI 0.79-0.93).
Figure 2. ROC curves for the prediction model of Swensen et al [1] and for a model combining Swensen 
pretest probability with 18FDG PET results.
Swensen: logistic probability model 
of Swensen et al.[1] 18FDG PET (4 
categories): 18FDG PET result in 
four categories (no uptake, faint, 
moderate and intense). Swensen + 
PET: the logistic model combined 
with 18FDG PET information.
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Figure . Nomogram using information from the clinical prediction model and 18FDG PET.
The probability of malignancy based on the value of Swensen et al [1] and the 18FDG PET result are 
indicated in the nomogram. First, the patient’s position on each predictor variable scale is defined. Each 
scale position has corresponding prognostic points located on the “points” scale at the top. These two 
numbers are then summed to arrive at a “total points” value on the total points axis. A vertical line is then 
drawn from the total points axis down to the probability to indicate the probability of malignancy.
Figure . Bootstrap calibration curve of the clinical prediction model of Swensen et al [1] with the 18FDG 
PET result (four categories) in 106 patients with SPNs.
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18FDG PET result and the prediction of Swensen et al combined
18FDG PET added to the predicted probability calculated by the Swensen [1] model improves 
the AUC by 13.6 (95% CI: 6-21; p=0.0003). The fitted function to calculate the probability 
of malignancy based on the model of Swensen together with 18FDG PET is as follows: 
probability of malignancy = 1 / (1 + e -x), with x = -4.739 + 3.691{Probability by Swensen 
(%)} + 2.322{faint uptake} + 4.617{moderate uptake} + 4.771{intense uptake}. A visual 
reproduction of the model is given in Figure 3 by means of a nomogram. The corresponding 
calibration curve displays the relation between the predicted and the actual probability in 
Figure 4. 
Discussion 
In 2003, a comprehensive cost-effectiveness decision analysis was published, which included 
the full spectrum of diagnostic and therapeutic options for SPNs.[2] The first stratification of 
this analysis was based upon the result of clinical risk assessment as provided by a previously 
developed multivariate logistic regression model.[1] It was recognized that this model, which 
was developed in a North-American population with pulmonary nodules discovered between 
1984 and 1986 and a prevalence of malignancy of 26.4% [1,7], required additional external 
validation. The current study provides validation of this clinical prediction model in a sample 
of patients with radiologically indeterminate nodules collected between 1997 and 2001, 
with a prevalence of malignancy of 57.5%. Our reported prevalence of 57.5% is more in line 
with other reports in the literature in which approximately one third of pulmonary nodules 
were radiologically indeterminate, and, of those, one third of the resected pulmonary 
nodules were benign.[8,9] However, in spite of differences in prevalence and prevailing local 
epidemiology of underlying diseases compared to the original data set of Swensen et al [1], 
the model showed a reasonable fit to our data, indicating that the model is robust. The 
calibration figure shows that the prediction model tended to underestimate the probability of 
malignancy, particularly at lower probabilities. Interestingly, in a follow-up study by Swensen 
et al,[7] in which the probability estimation of four experienced clinicians was compared with 
Table 2. Model characteristics
* VUMC: present study population. 1 Akaike’s Information Criterion. Lower values indicate more desirable 
models. 2 Goodness-of-fit test p-value [4]
Model N DF AIC1 ROC AUC 95% CI P-value 2
1. Full model of Swensen et al [2] 419 6 0.83 0.75
2. Validation set for Swensen et al [2] 210 6 0.80 0.62
3. VUMC*: Swensen model 106 1 120.2 0.79 0.70 - 0.87 0.46
4. VU: PET only 106 3 87.0 0.88 0.77 - 0.91
5. VU: Swensen model+PET 106 4 80.6 0.92 0.87 - 0.97 0.48
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the results of the prediction model, the clinicians tended to overestimate pretest probability 
particularly at lower values of the predicted probability. Obviously, clinical intuition and 
judgment of experienced clinicians are most important, but less experienced clinicians may 
be less accurate and more objective diagnostic techniques are still warranted. 
In our study, visual analysis of 18FDG PET proved to be an accurate method of interpretation. 
The AUC-ROC of 18FDG PET compared to the result obtained with the model of Swensen et 
al [1] did not significantly (p=0.058) improve predictive value (Table 2). However, the shape 
of the ROC curve (for the 18FDG PET) especially suggested though that the finding of actual 
patients having lung cancer (positive predictive value) improved. It could be argued that 
this was on the border of significance and reflected a type II error. On the other hand, we 
think that the actual difference of the 18FDG PET-alone model with the prediciton model of 
Swensen et al [1] is of little clinical importance since the parameters of the model of Swensen 
are always available prior to 18FDG PET.
Dewan et al [10] found that dichotomized results of 18FDG PET as a single test performed 
better than the standard criteria developed in a model by Cummings et al [11], including 
baseline prevalence, size, age and smoking history. However, the series by Dewan et al [10] 
was smaller, and the comparative model was based on Bayesian analysis combining likelihood 
ratios of test results that were assumed to be conditionally independent while derived from 
various sources. Our results suggest that with respect to diagnostic performance, the best 
results are to be expected from the combined information of clinical assessment and 18FDG 
PET (ie, the AUC-ROC showed a significant improvement (p=0.0003) as did the AIC of the 
combination model). Limitations of both 18FDG PET studies were their retrospective design as 
well as the potential of referral bias, which are other reasons for validation of the results. 
Clinical prediction rules and modeling can help to set the indication for PET scanning 
beyond the almost intuitive reasoning that 18FDG PET will be most useful in the 10-50% 
pretest probability range [2;12]. However, the results of complex decision models obviously 
depend on several assumptions. For example, it is not clear that the required strict pursuit 
of histopathological diagnoses can or will be obtained in clinical practice. In fact, it has been 
claimed that low 18FDG uptake (ie, the likely false negative ones) in T1 malignant lesions 
carries a relatively favourable prognosis,[13] but this has rightly not been accounted for in the 
model. Whether patients and clinicians will accept the strategy of watchful waiting in such 
cases remains to be seen. 
Even though we are aware that diagnostic accuracy measures are not directly related to patient 
outcomes, information as provided in the present study will at least help to define whether 
in individual cases the result of 18FDG PET might affect management. We expect that these 
limits may not be the same in different clinical situations. Therefore, a logistic model may, 
apart from calculating posttest probabilities, also help to decide whether 18FDG PET should 
be performed in an individual patient. After estimating the pretest probability of cancer, the 
clinician can assess which (if any) 18FDG PET result will push the diagnostic uncertainty beyond 
required limits. Since our analysis was based upon patients referred for 18FDG PET, we cannot 
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exclude the possibility of referral bias. Therefore, our model needs validation but since SPN is 
a major indication for 18FDG PET, this should not be a major problem. 
It has been pointed out that 18FDG PET studies in coin lesions contain a variety of criteria 
by which a PET result can be assigned a positive result. This is of concern when considering 
implementation of the technique. For practical purposes, the quantitative potential of 18FDG 
PET is often reduced to semi-quantitative measures like the standardised uptake value (SUV), 
which basically expresses the concentration of 18FDG uptake in a lesion as a function of 
the total injected dose. In comparison with visual image analysis, this approach has the 
conceptual advantage of objectiveness. However, the results of SUV measurements are also 
prone to heterogeneity due to prevailing differences in data acquisition and reconstruction 
methodology.[14] A visual analysis of 18FDG PET scan was performed because it has been 
shown that SUV methodology and implementation is less straightforward than was often 
assumed. There is still debate about the appropriate normalisations to be used, but, more 
importantly it has recently been demonstrated that results of SUVs strongly depend on 
image reconstruction methodology, level of noise, image resolution and region of interest 
definition, so that its use is highly questionable for generic diagnostic purposes.[15] 
Moreover one systematic review failed to show that semiquantitative image interpretation 
improves the accuracy of 18FDG PET.[3] Finally, the lack of standardisation in the current PET 
literature and practice strongly compromises the theoretical advantage of so-called objective 
measurements. The excellent reproducibility of visual scaling is probably explained by its 
close association with semiquantitative tumour/nontumour ratios. Our data suggest that 
visual assessment of 18FDG uptake intensity is a robust method. It is controversial whether 
attenuation correction improves detection. There is general agreement that localisation of 
abnormalities can be simplified by this correction, but this is not the issue in coin lesion 
characterisation. The downside of attenuation correction is a loss of patient throughput by 
about 30% due to the time needed for the acquisition of transmission scans necessary to 
obtain an accurate attenuation map. Even though calibration of our data with attenuation 
corrected scans is required, we do not expect a major impact since our accuracy data nicely 
fit into the summary ROC curve of the 2001 metaanalysis.[3] 
Conclusion
The clinical prediction model of Swensen et al [1] has been proven to have external validity. 
However, especially in the lower range of its estimates, the model may underestimate the 
actual probability of malignancy. Visual analysis of 18FDG PET is a robust and accurate method 
in radiologically indeterminate SPN. The combination of visually read 18FDG PET scans and 
pretest factors appears to yield the best accuracy. These results can help to adjust diagnostic 
workup in individual situations. 
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Abstract 
Background: A study was undertaken to study the effect of 18F-fluorodeoxyglucose (18FDG) posi-
tron emission tomography (PET) on diagnosis and management of clinically problematic patients 
with suspected non-small cell lung cancer (NSCLC). 
Methods: A prospective before-after study in a cohort of all 164 patients (university / community 
settings) referred for 18FDG PET between August 1997 and July 1999. 18FDG PET was restricted 
to cases where non-invasive tests failed to solve clinical problems. The impact on diagnostic 
understanding and management was assessed using questionnaires (intended treatment with-
out 18FDG PET, actual treatment choice after 18FDG PET, post hoc clinical assessment).
Results: Diagnostic problems especially pertained to unclear radiological findings (n=112; 63%), 
mediastinal staging (n=36; 20%) and distant staging issues (n=16; 9%). 18FDG PET findings were 
validated by reviewing medical records. 18FDG PET had a positive influence on diagnostic under-
standing in 84%. Improved diagnostic understanding solely based on 18FDG PET was reported 
in 26%, according to referring physicians, 18FDG PET resulted in beneficial change of therapy in 
50%. Cancelled surgery was the most frequent therapy change after 18FDG PET (35%). 
Conclusion: 18FDG PET applied as “add-on” technology in patients with these clinical problems 
appears to be a clinically useful tool, directly improving therapy choice in 25% of patients. The 
value of increased confidence induced by 18FDG PET scanning requires further evaluation.
Introduction
Medical imaging technology is rapidly expanding and the role of each modality is being 
redefined constantly. Positron emission tomography (PET) using 18F-fluorodeoxyglucose 
(18FDG) has emerged as an accurate imaging modality in patients with lung cancer.[1-3] 
Potential clinical indications include the differential diagnosis of benign versus malignant 
disease, initial (preoperative) staging, evaluation of suspected recurrences, and follow up 
after treatment. The use of 18FDG PET in clinical practice is based predominantly on studies 
of technical performance and diagnostic accuracy.[4;5] To ensure an appropriate use of 
18FDG PET, such studies should be followed by an analysis of the impact of 18FDG PET on 
management decisions, outcomes of care, and cost-effectiveness. 
In the northwestern part of the Netherlands where this study was performed, a single PET 
scanner serves 2.7 million inhabitants, with 50% of its time slots available for clinical purposes. 
To restrict the use of 18FDG PET to those patients that may benefit most, a program has been 
developed to evaluate the clinical usefulness of 18FDG PET, investigating the cost-effectiveness 
of performing 18FDG PET on a routine basis in the preoperative staging of non-small cell lung 
cancer (NSCLC) [6] and its impact as an “add on” technique in specific problem cases. To 
measure the clinical value of 18FDG PET in the latter group, we performed a prospective 
before-after study in a cohort of clinically problematic cases, typically after an extensive 
conventional work-up. This study design was used during the early studies of computed 
tomographic (CT) scanning by Wittenberg et al [7] and allows a systematic assessment of the 
impact of a test on diagnostic understanding as well as on patient management within the 
clinical context.[8] 
Methods
To be eligible for 18FDG PET scanning, patients had to have suspected or proven NSCLC 
with a diagnostic problem which, according to the referring physician, could not be solved 
by conventional methods alone and in which the 18FDG PET result might affect patient 
management. In an attempt to restrict 18FDG PET scanning to such cases, referrals were 
only accepted after discussion of the case between this physician and the staff nuclear 
medicine physician in charge at the Clinical PET Centre of the VU University Medical Centre. 
PET scanning therefore typically followed an extensive conventional work-up. All patients 
routinely underwent laboratory tests, bronchoscopy, chest radiography and CT scanning 
extending from the neck to the upper abdomen (including liver and adrenal glands). 
Additional diagnostic tests were performed in cases with signs and symptoms suggestive of 
distant metastatic disease. Patients entered in randomised [9] or response monitoring trials 
[10] were not included in the present report.

Prospective use of serial questionnaires
Assessment of clinical value
The impact of 18FDG PET on diagnostic understanding, and therapy choice was investigated 
using three questionnaires (Fig 1). These questionnaires were to be completed by the referring 
physician before 18FDG PET scanning, shortly after 18FDG PET scanning, and about 6 months 
after18FDG PET scanning, respectively. In the first questionnaire, information was requested 
regarding the histological diagnosis (if known), a definition of the current diagnostic problem, 
a differential diagnostic consideration, the results of diagnostic tests already performed and 
any planned diagnostic tests. In addition, the referring physician was requested to outline 
the intended patient management plan if 18FDG PET scanning was not available. The second 
questionnaire requested information regarding the working diagnosis and planned treatment 
after 18FDG PET scanning in addition to any diagnostic tests that had been ordered as a 
direct consequence of the 18FDG PET scan result. In the final questionnaire, the referring 
physician was requested to convey the final diagnosis and to rate the overall usefulness of 
18FDG PET separately in terms of diagnostic understanding and therapy of choice according 
to the method of Wittenberg et al. [7] This method involves using a 5 point ordinal scale (Box 
1), with higher scores representing an increasing positive impact. 
All questionnaires were checked for internal consistency between the pre-PET intentional 
management (questionnaire 1) and post-PET actual management (questionnaire 3). In the 
case of inconsistencies, the referring physicians were asked to review the cases in question 
and to revise the overall clinical value rating accordingly and these data were used in the 
analysis. In the case of PET negative – that is, suspected benign – coin lesions, follow-up was 
extended beyond 6 months by examining the medical records of these patients.
Figure 1. Study protocol. * Suspected NSCLC, diagnostic problem insoluble by conventional imaging, 
potential impact on patient management.
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Management changes
Treatment (management) changes were considered “major” if treatment changed from one 
modality to another – for example, from medical to surgical/radiation/ no treatment or vice 
versa [11] – and “minor” if treatment changed within a modality – for example, altered 
medical, surgical or radiotherapy approach. 
PET imaging
Whole body 18FDG PET scans were performed with a dedicated PET scanner (ECAT EXACT 
HR+, CTI/Siemens). Emission scans, typically extending from mid-skull to mid-femur, were 
acquired in 2D mode, approximately 60 minutes after intravenous injection of 370 MBq (10 
mCi) 18FDG. Patients were asked to fast for at least 6 hours prior to the PET study. Oral 
intake of water was encouraged. 
18FDG PET scans were corrected for decay, scatter and randoms. Scans were reconstructed as 
128x128 matrices using filtered back projection with a Hanning filter (cut-off 0.5 cycles/pixel) 
resulting in a transaxial spatial resolution of 7 mm at full width half maximum. If possible, 
CT scan data were used for more precise anatomical localisation of 18FDG PET abnormalities 
suspected as being malignant. 
Referring physicians were informed by telephone of the result of the 18FDG PET scan and 
an advice to the next step. Clinicians were urged to verify clinically decisive PET findings by 
conventional means (histology, imaging, follow-up) and to ignore unconfirmed hot spots. 
18FDG PET findings were retrospectively validated by examination of the medical records of 
Box 1. Questionnaire on evaluation of 18FDG PET impact
Diagnostic understanding (DU)
D=1: 18FDG PET confused my understanding of this patient’s disease and led to investigations I 
would not otherwise have done
D=2: 18FDG PET confused my understanding of this patient’s disease but did not lead to any 
additional investigations
D=3: 18FDG PET had little or no effect on my understanding of this patient’s disease
D=4: 18FDG PET provided information which substantially improved my understanding of this 
patient’s disease
D=5: My understanding of this patient’s disease depended upon diagnostic information provided 
only by 18FDG PET (unavailable from any other non-surgical procedure)
Treatment choice (TC) 
T=1:  18FDG PET led me to choose treatment which in retrospect was not in the best interests of the 
patient
T=2: 18FDG PET was of no influence in my choice of treatment 
T=3:  18FDG PET did not alter my choice of treatment but did increase my confidence in the choice
T=4: 18FDG PET contribute to a change in my chosen treatment but other factors (other imaging 
tests, other diagnostic tests, changes in patient status) were equally or more important
T=5: 18FDG PET was very important compared with other factors in leading to a beneficial change 
in treatment
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the included patients. Histopathology and clinical follow up findings that showed a benign or 
malignant course were considered as a valid reference test. 
Statistical analysis
Differences in diagnostic understanding or treatment choice between the three indications 
were tested by means of a two sided Kruskal-Wallis test. Wilcoxon-Mann-Whitney test was 
used to test differences between two samples. Changes in treatment plans before and after 
18FDG PET were tested by the marginal homogeneity test.[12] 
Results 
During a 23-month inclusion period, 179 patients with suspected NSCLC were referred for 
18FDG PET scanning. The referring physicians included pulmonologists (76%), oncologists 
(7%), internists (6%), radiotherapists (6%), neurologists (3%) and surgeons (1%) from 21 
different university and community hospitals. Questionnaires were returned from 178 (99%) 
patients and a fully completed questionnaires (all questions answered) was obtained for 136 
(76%) patients. Specifically, questionnaire 1 was fully completed for 83% of the patients, 
questionnaire 2 for 92%, and questionnaire 3 for 98%. Indications for 18FDG PET could 
be subdivided in six groups: unclear radiological abnormality (including solitary pulmonary 
nodules and lung masses, n=112; 63%), staging of the mediastinum (n=36; 20%), distant 
staging issues (n=16; 9%), response monitoring (n=5; 2.8%), suspected recurrence (n=5; 
2.8%), and unknown primary (n=5; 2.8%). The present report focuses on the first three 
clinical indications.
In these 164 patients, the clinical work-up before 18FDG PET included laboratory tests, chest 
radiography, CT scan of the chest (including liver and adrenal glands) and bronchoscopy.[13]
In patients with distant staging problems (n=16) the work-up before 18FDG PET consisted of 
bone scintigraphy and radiographic studies in the three patients with clinical concerns about 
skeletal metastases; CT evaluation of the abdomen typically preceded referrals with suspect 
adrenal enlargement or liver lesions in which biopsy was considered not feasible or had been 
inconclusive. In two patients in which chest CT scan had shown additional and indeterminate 
pulmonary lesions, bronchoscopic examination had been negative and it was not conidered 
feasible to take biopsy specimens. In five patients with potentially solitary brain metastases, 
dissemination tests had included CT scanning (brain, chest, liver and adrenal glands) and 
bone scintigraphy. In general, the work-up of patients with unclear radiological findings 
before 18FDG PET scanning conformed to national guidelines.[13] 
The diagnostic problems concerning mediastinal staging leading to referral for 18FDG PET 
(instead of invasive mediastinal staging) included former mediastinoscopy, thoracotomy or 
radiotherapy, indeterminate invasive staging results, medical inoperability, and “to determine 
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the most appropriate surgical approach”. After careful evaluation we were unable to identify 
a specific reason for choosing 18FDG PET scanning as opposed to mediastinoscopy to 
determine mediastinal lymph node involvement in 10 patients. 
In 29 out of the 179 patients the initially formulated management plans (to be carried out 
if 18FDG PET had not been available) were not consistent with the final assessment of the 
impact of 18FDG PET. For example, the physician’s written plan before 18FDG PET was to 
perform a thoracotomy, and a thoracotomy was indeed performed but treatment choise was 
rated as 5 (18FDG PET was very important compared with other factors leading to a beneficial 
change in treatment). Such inconsistent assessments were revised by the referring physicians 
(specifically with respect to the questionnaire 3), and corrected in 28 cases.
 
Diagnostic understanding 
The impact of 18FDG PET on diagnostic understanding was analysed for each clinical indication 
(Table 1). Overall, 18FDG PET was solely responsible for improved diagnostic understanding 
(DU=5) in 26% (95% CI 19 to 33) of the patients and substantially contributed to diagnostic 
understanding (DU=4) in 58% (95% CI 50 to 65). The effect of the 18FDG PET result on 
diagnostic understanding was confusing and led to additional tests (DU=1) in 3% (95% CI 
1 to 6), and had no or little effect (DU=3) in 9% (95% CI 5 to 15). The impact of 18FDG PET 
on diagnostic understanding was not significantly different for the three clinical indications 
(p=0.45). There was no significant difference (p= 0.85) in diagnostic understanding ratings 
between 18FDG PET scans indicating malignancy where the tumour was finally proven to 
be malignant (true positives) and scans indicating benign disease where the lesion proved 
to be benign (true negatives). To evaluate the presence of a potential clinical learning curve 
of incorporating 18FDG PET scanning results, we compared the diagnostic understanding 
ratings of “early” patients (the first five patients) referred by a particular physician to the 
ratings of later patients (the sixth and subsequent patients). The ratings in later patients 
tended to be significantly higher (p=0.0192).
Table 1. The impact of 18FDG PET on diagnostic understanding (DU) ratings (defined in box 1)
DU=1 DU=2 DU=3 DU=4 DU=5 Missing Total
Radiological abnormality 3 6 12 61 29 1 112
Mediastinal staging 1 1 1 21 11 1 36
Distant staging 0 0 2 10 2 2 16
Overall 4 7 15 92 42 4 164
Diagnostic accuracy
Of the patients referred to resolve unclear radiological findings, 76 patients had a positive 18FDG 
PET scan result which proved to be true positive in 68 patients (89%). Thirty six patients had a 
negative scan reading –that is, no focally enhanced 18FDG uptake suspicious for malignancy–
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which proved to be correct (true negative) in 34 patients (94%) either by “wait and see” policy 
(n=32) or surgery (n=2). The mean duration of follow up in these patients was 20 months 
(range 6-36). In two patients the 18FDG PET scans proved to be false negative. These false 
negative cases included a patient with pulmonary fibrous tumour  (the patient underwent a 
curative pneumonectomy) and a patient with mantle cell lymphoma (diagnosed 1 year after the 
18FDG PET scan). In one patient the indeterminate solitary pulmonary nodule proved to be true 
positive at surgery but 18FDG PET was found to have missed micrometastatic involvement of 
mediastinal lymph nodes.
Of the patients referred for mediastinal staging, 24 patients had a positive 18FDG PET scan 
result of which 22 were proven to be true positive as shown by pathology in 16 patients and 
by follow up in six patients; one was proven to be false positive (as shown by pathology) 
and one patient was lost to follow up. Eleven patients had negative scan results which were 
found to be true negative in 10 patients (as shown by pathology in six patients and by follow 
up in four: mean time from PET to last chest radiograph or CT scan was 15 months, range 
13-17). In one patient the PET scan was found to be false negative (as shown by pathology). 
In one patient the scan trajectory did not include the mediastinum due to claustrophobia. 
Of the patients referred because of distant staging issues, 10 were found to be true positive 
(as shown by pathology in six patients, follow up in two, and radiology in two). Six patients 
proved to have a true negative 18FDG PET 
scan as shown by follow up in five patients 
(mean time of follow up 6 months, 
range 6-6). In one patient the 18FDG PET 
result proved to be false negative (bone 
metastases). 
Management changes
In 162 of the 164 cases studied explicit 
provisional therapeutic plans had been 
stated before 18FDG PET. In 103 patients 
this involved surgery. After 18FDG PET, 
surgery was the treatment most commonly 
abandoned (Table 2). 18FDG PET contributed 
to a decision to forego surgical treatment 
in 36 patients (35%; 95% CI 26 to 45) in 
whom it had been provisionally planned. 
Of the patients in whom surgery was not 
the proposed treatment before 18FDG 
PET (n=59), seven patients subsequently 
underwent surgery. In these patients the 
intended therapy had been observation in 
Treatment change No. of patients
Surgery to
Radiotherapy 6
Chemotherapy 11
Observation    18
Radiotherapy to
Surgery 1
Chemotherapy 2
Observation 3
Chemotherapy to
Surgery 2
Radiotherapy 0
Observation 2
Observation to
Surgery 3
Radiotherapy 4
Chemotherapy 1
Minor changes within
Surgery 14
Radiotherapy 9
Chemotherapy 2
Table 2. Treatment changes after PET (T=4/5, n=78)
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four patients, chemotherapy in two patients, and radiotherapy in one patient. There was a 
significant change in terms of the “impact” of treatment for the patient, mainly toward a less 
aggressive approach (surgerychemo-/radiotherapyobservation; p=0.0001). The impact 
of 18FDG PET on treatment was divided into major or minor changes as outlined previously. 
PET was responsible for changes of choice of treatment that were major in 55 patients (66%; 
95% CI 55 to 76) and minor in 28 patients (34%; 95% CI 24 to 45). 
 
Post hoc evaluation of treatment choice 
The impact of 18FDG PET on treatment choice was analysed for each scan indication (Table 
3). According to the attending physician, 18FDG PET was the most important factor leading 
to a beneficial change of treatment (TC=5) in 45 of 159 patients (28%; 95% CI 21 to 35) 
patients and contributed to such change (TC=4) in 34 (21%; 95% CI 15 to 28). 
Of the 134 cases in which the physician reported increased diagnostic understanding, 
therapeutic plans remained unchanged in 59 cases (44%). No significant differences in 
changes of treatment choice for the three different indications were found (p=0.65). 
Treatment choice ratings after PET scanning indicating malignancy when the suspected lesion 
was indeed found to be malignant were not different from scans indicating a benign lesion 
found to be benign (p=0.27). Like diagnostic understanding, the treatment choice ratings 
were significantly higher for later patients than for early patients (p=0.037). 
Table . The impact of 18FDG PET on patient management and its clinical assessment (treatment choice 
(TC) ratings as defined in box 1)
TC=1 TC=2 TC=3 TC=4 TC=5 Missing Total
Radiological abnormality 1 16 42 21 30 2 112
Mediastinal staging 3 11 10 10 2 36
Distant staging 3 4 3 5 1 16
Overall 1 22 57 34 45 5 164
Discussion
A new test that appears to be more accurate than the standard ones will generate a clinical 
demand, even if it’s effect on clinical outcome measures is still unclear. With scarce technology 
like 18FDG PET overconsumption may result precluding general accessibility. Evidence-based 
guidelines for routine use are therefore needed, so that the available scanning capacity can be 
adjusted to the expected demand. However, guidelines aim at the average patient and may 
not be applicable in specific situations. In this prospective, multicentre before-after study the 
reported clinical impact of 18FDG PET as an “add-on” technology to solve diagnostic problems 
in patients with suspected NSCLC was considerable. Clinical compliance with the 18FDG PET 
results was high, and 18FDG PET was reported to have led to beneficial management changes 
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(TC³4) in 50% of the patients in the three clinical situations investigated. In addition, a 
positive influence on diagnostic understanding (DU³4) by 18FDG PET was observed in 84% 
of the patients. Put in a more conservative way, 18FDG PET proved to be the key diagnostic 
tool in one of every four patients referred for 18FDG PET (DU/TC=5). 
Interestingly, we observed an increasing appreciation of 18FDG PET over time. Even though 
other explanations may also be valid, individual consultation and feedback as done in our 
setting, is known to improve patient referral patterns.[14] 
Interpretation of the classification of “important contribution” to treatment choice by 18FDG 
PET (TC=4) is not straightforward. It is recognised that, in most clinical situations, decisions are 
made on the basis of a number of factors. Patient management depends on the preoperative 
assessment of the probability of disease, which is a joint function of multiple diagnostic 
indicators such as signs, symptoms and test results together with the effectiveness of the 
invasive procedures that follow them. This complicates the assessment of the contribution 
of a single test to a change in patient management. Even though the phrasing of the 
“contributive” ratings (DU/TC=4) may benefit from accentuation, such positive perceptions 
may always contain a spectrum of clinical relevance which is difficult to translate into outcome 
measures. The assessment of the true value of “contributive” rather than directly decisive 
18FDG PET findings (TC=4 v TC=5) is therefore best done in a randomised study design. 
Some studies have recently addressed the clinical impact of 18FDG PET. The methodologies 
and patient spectra were variable, but the reported management changes (65-70% [15-
17]) are uniformly higher than those observed as a by-product in accuracy studies (10-59% 
[18,19]). This underlines the fact that management change is multifactorial and does not 
merely depend on a single test (such as 18FDG PET). Alternatively, “clinical value” studies may 
have overestimated the true clinical contribution of 18FDG PET. Firstly, the clinical impact of 
a new technology depends on the quality of the previous clinical work-up; poorly performed 
conventional staging before 18FDG PET scanning would overestimate its actual value. We 
therefore made an effort to restrict 18FDG PET referrals to cases in which conventional 
investigations had indeed been performed and had failed. As we have shown, this was 
the case in the majority patients. Further, a retrospective analysis of the pre-PET work-up 
showed adherence to internationally accepted guidelines in the majority of patients. Secondly, 
whether a specific test contributed significantly is a matter of judgement, and thus subject 
to disagreement, error and imprecise measurement.[8] This was, indeed, the case in our 
study; inconsistencies were identified in 18% of the questionnaire responses. To strengthen 
the evidence of before-after studies, independent reviewing of the data by experts has been 
suggested. This has been shown to reduce the presumed benefit of a new technology as 
assessed with this type of study design.[20] However, such findings may also reflect the 
heterogeneity of daily clinical practice in which patients are actually diagnosed and treated. 
Thirdly, unconscious bias of the referring clinicians in favour of the new technology may have 
affected the results. We cannot rule out that this has occurred but the opposite may also 
be true. Even though the sample was not randomly chosen, we found no such effect in the 
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medical records of the cases in which a prolonged follow up was needed and the data were 
derived from a broad spectrum of hospitals. 
The questionnaires used do confirm a distinction between the clinical impact of a test on 
diagnostic understanding, patient management, and (retrospective) clinical assessment of 
the appropriateness of these changes. The data clearly show that the perceived benefit of 
18FDG PET scanning consists of altered patient management but, to an even greater extent, 
of increased diagnostic understanding or confidence in cases where patient management 
was not altered. In their present form, the questionnaires do not allow estimation of the 
amount of clinical uncertainty. In our opinion, studies such as this may serve to estimate 
the relative merits of 18FDG PET for different indications within a specific clinical context. 
If 18FDG PET fails to show clinical impact, the presumed indication for 18FDG PET may be 
removed from the list, whereas promising results warrant further investigation. Our data do 
not represent consecutive patients presenting with a similar clinical problem, and as such, 
our results cannot be extrapolated to imply the routine use of 18FDG PET in all patients with 
suspected NSCLC. Estimation of the cost-benefit of such an application requires a direct 
comparison between patients subjected to 18FDG PET and conventional work-up. Such a 
study is currently ongoing in the Netherlands.
In summary, controlled implementation of 18FDG PET as a “last resort” diagnostic modality 
improved patient management in at least 25% of clinically problematic cases with suspected 
NSCLC. The combination of preliminary guidelines, intensive feedback, and prospective 
monitoring may promote the effective use of scarce technology. 
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Abstract
Background: The presence of (distant) metastases affects the therapy (operation) and prognosis of 
patients with non-small cell lung cancer (NSCLC). Fifty percent of the operations are futile due 
to the presence of locally advanced tumour or distant metastases. Therefore, more accurate 
preoperative staging is required with respect to the outcomes (reduction of futile operations) 
and costs. This study examines current staging procedure and assesses possible situations for 
incorporating 18F-fluorodeoxyglucose positron emission tomography (18FDG PET). 
Methods: A retrospective analysis was performed  to assess actual clinical practice in the staging 
procedure of 337 patients with NSCLC in two Dutch hospitals. Consequently, by combining these 
data of actual clinical practice with a literature review, a model was developed to determine the 
influence of 18FDG PET on the staging outcomes and the costs. In this model the accuracy and 
costs of PET can be varied as well as the extent of substitution of conventional diagnostic tests 
by 18FDG PET.
Results: Practice variation was found between the two hospitals with regard to the setting in which 
the diagnostic staging took place (hospitalisation, outpatient setting) and the extent of the use 
of mediastinoscopy. This was reflected in the costs and in the number of (futile) operations.
Conclusion: Hospitalisation is the major cost driver in these patients. From a cost viewpoint, the 
evaluation of 18FDG PET in a strategy after diagnostic imaging but prior to invasive staging 
seems most optimal. 
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Introduction
Non-small cell lung cancer (NSCLC) is diagnosed in approximately 9,000 patients per year 
in the Netherlands. The overall 5-year survival for stage I or II (local disease) is 50 to 60%, 
while survival decreases substantially in the more advanced stages. In general, the therapy 
for stage I and II is resection of the tumour; for locally advanced stages, combined systemic 
and local therapy is optional.[1,2] The strongest prognostic factor for survival is complete 
resection of the primary tumour. Therefore, it is crucial to optimise staging of the disease 
in order to initiate optimal treatment and determine resectability. Currently, the staging 
work-up of patients with NSCLC in the Netherlands encompasses several diagnostic tests. 
Standard practice includes bronchoscopy to obtain a histological diagnosis of the primary 
process, followed by imaging tests to select patients with localised disease for surgery, 
computed tomography (CT) of the chest and abdomen, usually followed by other tests, such 
as magnetic resonance imaging (MRI) of the brain, ultrasound, bone scintigraphy. According 
to guidelines, in the patients thereafter held to be candidates for surgery, invasive procedures 
(mediastinoscopy) are required before resection is planned.[3] Recent studies of NSCLC have 
shown that positron emission tomography (PET) using 18F-fluorodeoxyglucose (18FDG) is an 
accurate diagnostic tool e.g. for mediastinal lymph node staging.[1,3-8]
Rational decisions regarding the use of this new technology depend on the assessment of 
its effects and costs in comparison with the conventional diagnostic staging procedures.[9-
11] We have conducted a retrospective study to obtain data on the practice, efficiency 
and cost of staging cancer in these patients.[3] This article deals with the cost aspects 
and adds a methodology, in which the value and the costs of 18FDG PET are evaluated, 
using a modeling approach. Consequently, these findings have been used in the design of 
a randomised trial.[12] 
Methods
Study design
Assessment of current clinical practice encompassed a retrospective analysis of all consecutive 
patients with (suspicion of) NSCLC diagnosed in 1993 and 1994 in two hospitals: Academic 
Hospital Vrije Universiteit in Amsterdam (VUMC) and a community hospital, Medical Center 
Alkmaar (MCA).
Eligible patients underwent one or more of the following staging procedures: bronchoscopy, 
imaging (e.g. CT scan, bone scan, MRI, ultrasound) and invasive tests (e.g., mediastinoscopy). 
Thoracotomy is a diagnostic as well as a therapeutic intervention. It provides information 
on the presence of malignancy (if this has remained unclear) and on the resectability of the 
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tumour (diagnosis). If possible, the tumour is radically resected (therapy). In our analysis, we 
classified thoracotomy as a therapeutic intervention. 
Thoracotomy was classified as futile in case of benign lesions, recurrent disease within 1 year 
after definitive staging and surgery with curative intent, pathologically proven mediastinal lymph 
node involvement and exploratory (“open and close”) procedure for any reason. The number of 
correctly staged patients and its corresponding costs are the endpoints of the study.
Costs
The costs of the diagnostic strategies were made up of two components: the volume of 
medical activities, as assessed in our retrospective analysis, multiplied by their monetary 
valuation. Only direct costs made within the healthcare sector were calculated. Detailed 
price calculations were made in two hospitals to estimate unit costs reflecting the real use 
of resources. These calculations included the costs of manpower, materials, equipment and 
overhead.
Calculation of the cost of the PET scan required additional effort. A fully equipped PET centre 
as operational in the clinical PET centre of VUMC includes the scanner, the cyclotron and 
the radiochemicals. The radioactive tracer 18FDG has a physical half life of 110 minutes and 
is therefore transportable over longer distances; thus PET scanning does not necessarily 
require a cyclotron in the same hospital (the satellite concept [13]). Typically, 370 MBq 
of 18FDG is administered to adult patients. The loss of activity due to the time interval 
between production and administration to the patient needs to be accounted for in the 
costs. In the present analysis, we excluded the costs of subsequent therapeutic interventions 
(chemotherapy, radiotherapy).
Results
Patient data
In total, 337 patients were evaluated: 220 patients in the MCA hospital and 117 patients in 
the VUMC hospital. Patient characteristics (gender, age) were similar in both groups. Final 
preoperative staging resulted in 45% of all patients with stage I or II at the MCA hospital and 
59% at the VUMC hospital.
The total number of futile thoracotomies  amounted to 44% in the MCA hospital and 64% 
in the VUMC hospital. The mean number of (invasive) diagnostic tests between two patients 
groups (surgery vs. no surgery) in both hospitals is summarised in Table 1. These diagnostic 
tests included all imaging as well as the invasive tests (bronchoscopy and mediastinoscopy).
No significant differences in the mean number of diagnostic tests were seen between both 
patient groups and both hospitals. However, the number of patients who underwent invasive 
diagnostic testing (mediastinoscopy) differed between the various patient groups in both 
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hospitals. Mediastinoscopy was performed  in the majority of patients in the MCA hospital, 
which reflected the practice variation. 
Table 2 shows the full costs of the diagnostic tests and admission days necessary for staging 
and surgery (intensive care days, hospital days). These prices are the mean prices as calculated 
in both participating hospitals.
Consequently, we calculated the total costs of the various staging procedures for all 
patient groups. Table 3 shows the differences in costs as related to the practice variation. 
For example, in the MCA hospital, preoperative staging takes place in hospital, if there is 
suspicion of the presence of NSCLC, in order to accelerate the procedure. In the VUMC 
hospital, however, preoperative staging takes place in an outpatient setting. The difference 
in the use of a mediastinoscopy between both hospitals is also depicted, but this has less 
impact on the total cost compared with the hospital length of stay, even if this procedure 
Table 1: Patient characteristics and hospital practice variation in both hospitals
MCA
(n = 220)
VUMC 
(n = 117)
Age (mean) 66 63.7 
Male gender (%) 177 94
Final pre-operative staging:
Stage I/II (%) 99 (45) 69 (59)
Stage III/IV (%) 121 (55) 48 (41)
No. of operations in stage I/II patients (%) 85 (86) 59 (86)
No. of futile operations (%) 37 (44) 38 (64)
Operated patients and mean number of diagnostic tests 4.9 5.3
Not operated patients and mean number of diagnostic tests 4.7 5.6
Operated patients and mediastinoscopy (%) 57 (67) 9 (15)
Not operated patients and mediastinoscopy (%) 37 (27) 4 (7)
A: diagnostic tests Mean cost price (€)* 
Hospital day 216
Intensive care day 1,163
Ultrasound abdomen 68
CT scan 123
Bone scan 243
MRI 185
Brochoscopy (flexible) 62
Bronchoscopy (rigid) 167
Mediastinoscopy 361
 18FDG PET 1,588
* Mean prices calculated in the two participating hospitals (1 € = 2,2037 DFL)
Table 2: Mean costs prices of the various staging procedures (€) and PET
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is accompanied by several admission days in the hospital. The total costs for the diagnostic 
staging procedure is higher in the MCA hospital, due to the hospitalisation and the higher 
number of mediastinoscopies. 
Cost price 18FDG PET
Before introducing PET in the staging process, we calculated the full cost of 18FDG PET. 
For this calculation, the following information is important: the duration of the 18FDG PET 
examination, the annual number of 18FDG PET scans, the quantity of radiopharmaceuticals 
Table : Cost prices of the various staging procedures in both hospitals (€)
MCA (n=220) No surgery 
(n=135)
Unsuccessful surgery 
(n=33)
Successful surgery 
(n=52)
Diagnostic staging:   
Number of hospital days 14 15 14.4
Total hospital admission costs 2,604 2,759 2,642
Imaging tests 243 231 214
(non-) invasive test 143 280 267
Total costs (preoperative) 2,99 3,27 3,123
Operation costs   
Number of intensive care days - 4 4.4
Total costs of intensive care - 4,803 5,605
Number of hospital days - 12 12
Total hospital admission costs  - 2,22 2,265
Operation - 1,477 1,477
Total cost (postoperative) - 8,5 9,346
Total costs 2,99 11, 12,
VUMC (n=117)  (n=58)  (n=38)  (n=21)
Diagnostic staging:
Number of hospital days - 7 6.5
Total hospital admission costs  - 1,671 1,631
Imaging tests 418 318 274
(non-) invasive test 80 109 78
Total costs (preoperative) 497 2,097 1,983
Operation costs  
Number of intensive care days - 1 2.7
Total costs of intensive care 802 2,854
Number of hospital days 12 13
Total hospital admission costs  2,96 3,226
Operation 1,526 1,526
Total cost (post-operative) 5,289 7,606
Total costs 9 ,8 9,89
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administered, the staff employed and the mode of obtaining 18FDG (transportation).[13]  If 
we assume six diagnostic PET scans daily, 1,500 scans per year, and a cyclotron in hospital, 
the average cost of a 18FDG PET scan amounts to E1,588. This reflects the present situation 
for the Amsterdam PET centre, where the available scan (a full-ring PET scanner) is equally 
divided between clinical and research applications. It is clear, that if the production and the 
application change, it will be reflected in the cost of the procedure.
Modeling
From this study, we calculated the difference in average costs per patient in the PET strategies 
versus the conventional staging process. Decision tree models were constructed for various 
competing strategies for the inclusion of 18FDG PET in the staging process (Figure 1).
The first strategy (PET 1) included the incorporation of 18FDG PET in the initiation phase of 
the staging process. In this strategy, all patients are diagnosed by 18FDG PET. The second 
strategy (PET 2) uses 18FDG PET after medical imaging but prior to invasive staging. The 
third strategy (PET 3) includes the incorporation of 18FDG PET after medical imaging and 
mediastinoscopy; patients eligible for surgery are diagnosed by 18FDG PET.
The possibilities for introducing 18FDG PET depend on its accuracy and degree of substitution 
in the current diagnostic work-up. We must make some valid assumptions beforehand. From 
a literature review, we know that the accuracy of 18FDG PET is better than in conventional 
clinical practice. We assume an accuracy of 80% in strategy 1 and 2 and an accuracy of 
74% in strategy 3.[14] Furthermore, we assume a constant use of health care resources 
within each strategy after introduction of 18FDG PET. An additional issue is the question if 
incorporation of 18FDG PET will result in a substitution or addition of the conventional staging 
procedures. An advantage of a modeling approach is the possibility to varying the level of 
substitution of 18FDG PET in the diagnostic work-up process and its consequent impact on 
the costs. Various levels of substitution are taken into account by varying the percentages, 
which indicate the levels of substitution, e.g. 0% indicates that all other diagnostic tests (and 
subsequent hospital admission days) are substituted by 18FDG PET, while 100% indicates that 
PET is merely added to the staging procedures.
Because the two hospitals differed in staging practice, we applied the calculations to the hospital 
with the most common applied staging procedure in clinical practice which was the VUMC. 
Patients with other diagnoses than NSCLC were included in the cost analysis. Patients eligible 
for surgery, who were not operated due to other medical reasons, were excluded from the 
accuracy analysis; we therefore included 107 patients. Consequently, by varying the accuracy of 
PET and the extent of substitution, we were able to determine a cost-neutral strategy. 
As is shown in Figure 1, including 18FDG PET leads to a shift in the number of futile operations 
from 38 to17 and to a corresponding higher number of patients not receiving surgery in the 
first strategy. 18FDG PET decreases the number of futile operations from 13 to 8 patients 
in the subgroup receiving a mediastinoscopy, and to 17 in the second and third strategy 
respectively. 
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Figure 1. Actual clinical practice of the VUMC and the various 18FDG PET strategies
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Figure 2. 18FDG PET and percentage substitution (VUMC)
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The resulting costs, within a varying degree of substitution, are depicted in Figure 2. On 
the horizontal axis the degree of substitution is shown, whereas the additional costs are 
presented on the vertical axis. The bold line shows the additional preoperative staging costs 
per patient when 18FDG PET is incorporated in the staging process. The thin line shows the 
total additional costs per patient, including the operation and hospitalisation costs. 
Complete substitution (100%) results in an additional E 307 per patient (E 1,588 PET costs 
minus conventional staging costs of E 1,281). When PET is completely added (0%), it will 
result in an additional E 1,588 for each patient.
The downward shifting of the bold to the thin line shows the extent to which PET decreases 
the number of futile operations. If the accuracy of 18FDG PET equals the conventional staging, 
both lines coincide. A better accuracy of 18FDG PET results in a  further downshifting of the 
thin line. 
As shown in Figure 2, the staging costs are always above the x-axis, in contrast to the total 
additional costs. Its surface under the x-axis represents a decrease in costs, whereas the 
surface above the x-axis represents an increase in total costs. The surface of the area under 
the x-axis amounts - E 160, and the surface above the x-axis amounts + E 160, resulting in 
no increase of costs per patient.
With a substitution level of 50%, the additional total costs per patient staged with PET are 
equal to the costs in the current work-up in the VUMC, as is shown at the intersection of the 
total cost line with the x-axis. 
The second strategy has a higher probability resulting in a decrease of costs compared to 
the first strategy. Complete substitution (100%) results in a decrease of - E 165 per patient. 
Complete addition (0%) will result in an additional E 221 for each patient.
The surface of the area under the x-axis for the total costs amounts - E 35 and the surface 
above the x-axis amounts + E 63, resulting in an additional decrease of  E 28 per patient. 
With a substitution level of 43%, the additional total costs per patient staged with PET are 
cost-neutral.
For the third strategy, the percentage substitution is not an issue, since all patients have a 
similar diagnostic work up as in the conventional procedure. Only patients eligible for surgery 
are diagnosed by 18FDG PET. Therefore, both lines in the figure run horizontal. The bold line 
is determined by the proportion operations rather than the number of patients eligible for 
surgery. As shown in the actual clinical practice data, 50.4% of the patients are operated and 
consequently are eligible for 18FDG PET, which determines the height of the line of  E 801. 
Due to the increased accuracy of 18FDG PET, the total average costs are decreased to E 146. 
From our analysis, it is concluded that introduction of 18FDG PET for all patients will lead 
to a substantial increase in staging costs, which are partially offset by a reduction in futile 
operations, given a certain amount of substitution of the current diagnostic work-up. 18FDG 
PET prior to invasive staging will lead to a more limited increase in staging costs, which are 
offset at a lower level of substitution of other diagnostic tests and therefore seem to be more 
2
Chapter 6
efficient. Reserving 18FDG PET only for patients eligible for surgery will always lead to an 
increase in costs.
Introduction of 18FDG PET will inevitably lead to an increase in staging costs, irrespective of 
the strategy. By declining the number of futile operations, the total costs can be contained. 
Certain possibilities and risks accompany each strategy. 18FDG PET in strategy 1 leads to an 
important increase in costs, but also to an important decrease in total costs. The cost risks in 
strategy 2 are small, but are accompanied by a small reduction in futile operations. For both 
strategies, the accuracy and amount of substitution are the major risks. For the third strategy, 
only the accuracy of 18FDG PET weighs. Finally, the cost price of 18FDG PET in the model can 
be varied, using a sensitivity analysis approach. 
Discussion
PET was developed initially by scientists at Washington University in the late 1970s. PET 
promised the possibility of imaging physiological changes in the brain, and was seen initially 
as a unique tool for physiological research. Clinical applications were anticipated. By 1981 the 
first commercial PET scanner was available. Despite the high price of the technology ($2 to 3 
million in 1981), application of the technique in the study of tumours, epilepsy, and cardiology 
appeared to be promising, especially since the tracer 18FDG proved to have a high affinity for 
relevant tissues as well as a favourable biodistribution. But the costs and effectiveness of its 
use in routine clinical practice remains unknown. Recently, the UK standing Group on Health 
Technology concluded that existing evidence on the diagnostic accuracy of 18FDG PET scan is 
limited, because the clinical trials were liable to bias.[12] Furthermore, evidence on the cost-
effectiveness of PET in various clinical indications is lacking. There is no good insight on how 
18FDG PET will effectuate cost-effectiveness in the diagnosis, prognosis and management of 
patients. 
Decisions on the deployment of the 18FDG PET technique are also being made in the 
Netherlands. Prior to the performance of a randomised clinical 18FDG PET trial, we have 
formulated a step-to-step course to evaluate the introduction of new diagnostic technologies 
in general.
The first step encompasses signalling of (in-) efficiency in the existing clinical practice. From 
our analysis, it was concluded that the percentage of futile operations was very high, that the 
diagnostic work up varied considerably, concentrated on the number of mediastinoscopies 
performed and that the hospitalisation days constituted the major cost driver.
However, is it possible to decide whether there is sufficient inefficiency at the current practice 
to justify the introduction of a new test? If not, one could write a recommendation immediately 
with this outcome. If there is sufficient inefficiency, we turn to step 2, in which literature 
analysis on accuracy of the new technology plays a major role. Combining the clinical practice 
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and the accuracy considerations, this technology can already be recommended for certain 
indications, as was shown in our analysis. Hereafter, one could perform prospective cost-
effectiveness research (step 3), ideally in trial form (randomised). Setting up a randomised 
controlled trial is difficult and expensive; this should only be contemplated with high chances 
of health gain and shifting costs, and at specific indications that have the highest chance 
of occurring the disease. Stage 4 emphasises scenario analysis for testing robustness of 
assumptions and for extrapolating to other relevant situations (eg, additional cost-research 
with focus on the Dutch situation). The final step includes setting up and implementing 
guidelines in co-operation with professional associations. This step marks the transition to 
policy development of pure scientific to more social considerations. This means, for example, 
that introducing a new diagnostic technology involves other factors, such as clinical relevance, 
minimisation of discomfort, minimisation of risks, and the time within medical information is 
available.
Our study can be regarded as an important baseline study for the evaluation of new 
technologies. By evaluating the actual clinical practice, we noticed a considerable practice 
variation in the staging process. By analysing the introduction of PET by using a model, 
we conclude that the greatest impact of PET in effectiveness and costs lies in the second 
strategy of the staging process.
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Abstract
Purpose: We investigated whether application of 18FDG PET immediately after first presentation 
might simplify staging while maintaining accuracy, as compared to traditional strategy in routine 
clinical setting. 
Methods: At first presentation, patients with a provisional diagnosis of lung cancer without overt dis-
semination were randomised to traditional work-up (TWU) according to international guidelines 
or early PET followed by histological/cytological verification of lesions, or imaging and follow-up. 
Patients with 18FDG avid, non-central tumours without suspicion of mediastinal or distant metas-
tases on PET proceeded directly to thoracotomy. Follow-up in presumed benign lesions was at 
least 12 months. In patients treated with surgery or neoadjuvant therapy, the quality of staging 
was measured by comparing the clinical stage to the final stage (combination of peroperative 
staging and 6 months of follow-up). To investigate test substitution, the number of (non)invasive 
tests to achieve clinical TNM staging and its associated costs were analyzed. 
Results: Between 1999 and 2001, 465 patients (233 TWU, 232 PET) were enrolled by 22 hospitals. 
The mean (standard deviation) number of procedures to finalize staging was equal in the TWU 
and PET arms, 7.9 (2.0) versus 7.9 (1.9); p=0.90, respectively. Mediastinoscopies occurred signifi-
cantly less often in the PET arm. Agreement between clinical and final stage was good in both 
two arms (Kappa 0.85 vs. 0.78; p=0.07). Costs did not differ significantly.
Conclusion:  Up-front 18FDG PET in patients with (suspected) lung cancer does not reduce the over-
all number of diagnostic test but it maintains quality of TNM staging with the use of less invasive 
surgery.
Introduction
Evaluation of patients suspected of non-small cell lung cancer (NSCLC) includes diagnosis and 
staging of the primary lesion and assessment of the extent of locoregional and metastatic 
spread. Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18FDG) provides 
useful information in NSCLC staging. The focus of research beyond accuracy measures 
focused on the added value of PET to conventional work-up if positioned just before to 
surgery.[1-5] Results of accuracy studies suggest however that application of 18FDG PET up-
front in NSCLC diagnostic work-up could also be considered to simplify and improve staging 
and patient management. 18FDG PET applied early in the diagnostic process might reduce 
the number of investigations, iatrogenic morbidity and diagnostic delay, and facilitate rapid 
institution of curative or palliative therapy. Costs of diagnosis and therapy might be reduced 
if verification of a single decisive lesion suffices to assign appropriate treatment.
The aim of this randomised trial was to investigate whether application of 18FDG PET as an 
up-front whole body test improves the process of staging patients suspected to have NSCLC 
without losing accuracy at reasonable costs.
Patients and methods
Patients
Immediately after clinical suspicion of lung cancer had arisen based upon history, physical 
examination and chest X-ray, patients were invited to participate. Additional inclusion criteria 
were absence of clinically overt disseminated disease at first presentation, age greater than 18 
years and being medically fit for staging and surgery. Exclusion criteria were pregnancy and 
diabetes. Patients had to give written informed consent according to local ethics committee 
regulations. Twenty community and two university hospitals recruited patients.
Procedures
Patients were randomly assigned to ‘traditional’ (TWU) or ‘PET up-front’ work-up (PET), 
centrally by computer, by a permuted block design, stratified by institute and (Eastern Co-
operative Oncology Group [ECOG]) performance score (0-1 versus 2-3). Patients allocated to 
TWU underwent imaging (without 18FDG PET ) and invasive procedures to establish diagnosis 
and assess operability and resectability according to international guidelines.[6] Staging in 
the PET group started with a 18FDG PET  scan, which was interpreted in conjunction with 
available clinical information and chest x-ray. PET scans were performed within one week 
after randomisation. In either arm suspected locoregional and haematogenous metastases 
had to be verified by biopsy, or when this was not possible by imaging and follow-up. In 
the PET arm, invasive confirmation was advised if PET suggested mediastinal lymph node 
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involvement but no distant metastases. Mediastinoscopy was advised if the primary tumour 
appeared adjacent to the mediastinum at 18FDG PET, for the reasoning that the spatial 
resolution of PET does not allow to separate neighbouring mediastinal nodes and primary 
tumour.[7;8] Surgery was recommended if the primary lung lesion was 18FDG avid without 
evidence of mediastinal involvement, and distant metastases.[7] Since 18FDG PET  is relatively 
insensitive for brain metastases, clinicians were instructed to perform computed tomography 
(CT) or magnetic resonance (MRI) of the brain if clinically indicated. A “wait-and-see” policy 
was acceptable if the primary lung lesion was negative at 18FDG PET. However, when 
clinicians still wanted further diagnostic information they were instructed to perform staging 
procedures according to standard practice. All tests and procedures other than 18FDG PET, 
including treatment and follow-up, were performed in the referring hospitals. Follow-up (up 
to one year after randomisation) consisted of 3-monthly visits, including at least physical 
examination, chest x-rays or imaging of indicator lesions in case of “wait-and-see” policy. 
Figure 1 summarizes the study design. Stages were recorded using the TNM system.[9] 
PET imaging and analysis  
PET scanning was performed in two centres (VU Medical Center, Amsterdam; University 
Medical Center Groningen) with Siemens ECAT EXACT HR+ scanners (Siemens/CTI, 
Knoxville, TN, USA). Patients fasted for 6 hours prior to scanning with free access to water. 
Emission scans were acquired in 2D mode, starting 90 minutes after intravenous injection 
of approximately 370 MBq 18FDG (if bodyweight > 85 kg: 550MBq). Emissions scans were 
performed for 5 min/bed-position from knee-joint to skull vertex followed by transmission 
scanning of the thorax (3 min/bed-position). Scans were corrected for decay, scatter and 
randoms and reconstructed using ordered subset expectation maximization (OSEM) with 
2 iterations and 16 subsets followed by post-smoothing (Hanning 0.5 filter; transaxial 
spatial resolution 7 mm full-width at half-maximum). In either centre, two experienced 
nuclear medicine physicians visually interpreted the PET scans. Focally enhanced uptake 
outside the physiological biodistribution of 18FDG was considered abnormal. Disagreement 
in interpretations were resolved by consensus, if necessary using a third reader. The final 
PET report included information on the nature of the primary lesion, the presence of 
nodal involvement and distant metastases, and concluded with an assessment of TNM 
stage according to PET and a suggestion for further work-up. Typically, the T classification 
consisted the likelihood of malignancy of the primary rather than its extension which cannot 
be assessed reliably at PET.[10] This was communicated to the referring clinicians by phone 
and confirmed in writing, including a hard copy of PET-images. 
Data analysis 
In each patient, clinical stage assigned by the attending clinician was compared to the 
final TNM stage established at surgery and/or follow-up. The attending physician assigned 
a ‘clinical stage’ (c-TNM) using the results of pretherapeutic diagnostic tests. This ‘c-TNM’ 
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Figure 1A, B, C. Study design. 
C. PET strategy: mediastinum 18FDG negative
B. PET strategy: mediastinum 18FDG positive
A. Randomisation
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stage was compared to the final stage as established by 1) biopsy and/or imaging test 
results and 6 months follow-up (typically patients with stage IIIB/IV), 2) a combination of 
surgicopathological staging and 6 months’ follow-up (thoracotomy patients), 3) the results at 
12 months after randomisation in patients with a provisional diagnosis of a benign primary 
lesion. In patients who had no thoracotomy due to presumed distant metastasis, and in 
whom imaging rather than pathology results had been used to establish the final stage, an 
adjudication committee of three experienced pulmonary physicians reviewed the records to 
decide whether this clinical classification had been appropriate. We considered staging of 
lung lesions proving to be metastasis from a primary tumour not identified at clinical work-up 
as incorrect. If the presenting lung lesion proved to be a single metastasis from a previously 
known tumour, clinical stage was considered correct provided that no new metastases of 
the same malignancy became apparent within 6 months. All tests were recorded including 
procedures to assess resectability and operability (medical fitness). We classified tests as non-
invasive (laboratory, functional tests [including ventilation/perfusion scintigraphy, lung and 
cardiological function tests] and imaging) and invasive (biopsies, surgical procedures). 
 
Outcome measures 
Primary outcome measure was the number of tests and procedures to finalize staging and 
to define operability. Quality of staging was assessed with the number of correctly clinically 
staged patients compared to the final stage as determined at surgery and/or follow up. 
Secondary outcome measures included duration of diagnostic processes, morbidity due to 
complications of diagnostic procedures, and costs of diagnostic and therapeutic processes. 
Costs
We calculated total costs from a hospital perspective, implying that only direct medical 
costs were taken into account. These costs consisted of diagnostic tests (ie, investigations to 
assess functional operability, staging procedures), therapeutic interventions (ie, thoracotomy, 
chemotherapy, radiotherapy), outpatient visits and hospital admissions.
The full costs of the various diagnostic and therapeutic procedures were calculated using 
the micro-costing approach [11], including costs of personnel, materials, depreciation and 
overheads, calculated as average costs from one general and one university hospital based 
on 2003 Dutch prices. The costs of 18FDG PET included costs of personnel, depreciation and 
maintenance, 18FDG, and overheads.[3] 
Statistical analysis
Primary endpoint was reduction of number of diagnostic investigations. In an earlier obser-
vational study in two participating hospitals, at least 3 (mean, 3.2; standard deviation [SD], 
1.6) diagnostic procedures in half of the patients were performed on top of bronchoscopy, 
chest x-ray, laboratory, lung function and cardiovascular tests and thoracotomy.[12] Here, we 
considered the PET up-front strategy clinically useful if the proportion of patients needing at 
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least 3 tests would be reduced from 50 to 30%. Furthermore, we anticipated to include 30% 
with other histologies (e.g. Small Cell Lung Cancer, benign lung diseases) for which 18FDG PET 
might have a different impact. Therefore, to sufficiently reliably assess the impact in the patient 
sample of interest its size was increased by 30%, to a total of 465. Differences in the number of 
different combinations of tests and duration of diagnostic processes were tested with a t test. 
Decreasing the number of diagnostic procedures should not result in reduction of quality of 
staging. The latter was measured by overall agreement between clinical and final TNM stage 
using Kappa statistics. Considering NSCLC patients only, we applied weighted Kappa statistics 
(Kappa has a maximum of 1.0 with perfect agreement; zero indicates no agreement better 
than chance). Costs data were compared with two-sided Wilcoxon-Mann-Whitney tests.
Results
Baseline characteristics
Between September 1999 and June 2001, 2114 potential patients were seen in the 22 
participating hospitals; of which 465(22%) were enrolled in this study, 233 in the TWU group 
and 232 in the PET group. One patient allocated to TWU declined further investigations 
after randomisation. Two patients allocated to PET declined PET and nine allocated to TWU 
underwent PET. All patients were included in the “intention-to-diagnose” analysis. Baseline 
characteristics such as age, sex, ECOG performance scores, weight loss, co-morbidity and 
history of malignancy were well balanced in both groups (Tables 1 and 2). Initial clinical 
staging did not differ significantly between TWU and PET group (Tables 2 and 3). In the 38 
reviewed records of patients with presumed stage IV, in whom imaging rather than pathology 
results established the final stage, classification was considered to be appropriate. 
Table 1. Patient characteristics, demographics
TWU N=233 PET N=232
Characteristic
Age (years, mean [SD]) 65 (10) 63 (10)
Sex  
Men 155 (67%) 158 (68%)
Women 78 (33%) 74 (32%)
ECOG performance score
0-1 219 (94%) 227 (98%)
2-3 14 (6%) 5 (2%)
Weight loss >5 % 72 (31%) 68 (30%)
Previous malignancies 33 (14%) 35 (15%)
Vascular comorbidity 68 (29%) 55 (24%)
Final diagnosis of NSCLC 131 (56%) 118 (51%)
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Primary outcome 
The proportion of patients requiring at least 3 tests (on top of bronchoscopy, chest x-ray, 
laboratory measurement, lung functional and cardiovascular tests and thoracotomy [12]) was 
52% in the TWU arm compared to 51% in the PET arm (p=0.82). Their total number in order 
to finalize staging was similar in TWU and PET arm. A mean (SD) of 7.88 (1.95) and 7.90 
(1.88) tests (TWU and PET, respectively) was needed for staging in NSCLC (p=0.90). We 
found no significant difference in the total number of diagnostic procedures. 
All patients staged as I/II and IIIa in TWU arm underwent recommended tests (laboratory 
tests, chest X-ray and CT of chest through liver and adrenals). In patients with stage I/II 
invasive mediastinal staging was performed in 66% (56/85,95% CI 0.55 to 0.76), and in 
45% at least one test procedure (except CT of chest through liver and adrenals) was done 
to identify distant metastases (38 of 85, 95% CI 0.34 to 0.56). In patients with clinical stage 
IIIa invasive mediastinal staging was performed in 74% (14/19, 95% CI 0.49 to 0.91), at least 
Table . Tumor types in patients with other lung malignancies or different metastatic diseases after 
clinical staging.
TWU PET
Other lung malignancies
SCLC 23 11
Mesothelioma 1
Sarcoma 1
Mucoepidermoid carcinoma 1
Metastatic (non-lung)
Colorectal carcinoma 1 1
Thyroid carcinoma 1 1
Prostate carcinoma 1
Lymphoma 1 1
Renal cell carcinoma 1 2
Table 2. Distribution of stages of NSCLC at the end of clinical staging period, metastatic and other 
primary lung malignancies and benign abnormalities.
* One patient with missing data. No difference between TWU and PET group, comparing groups by Pearson’s 
Chi-square (nominal) (p=0.24), Kruskal-Wallis (ordered) (p=0.18).
TWU N=233* PET N=232
Benign 27 (12%) 41 (18%)
I/II 85 (36%) 92 (40%)
IIIA 19 (7%) 16 (7%)
IIIB 35 (15%) 24 (10%)
IV 33 (14%) 39 (17%)
Synchronous lung cancer [24] 3 (1%) 3 (1%)
Other primary lung malignancy 26 (11%) 11 (5%)
Metastatic (non-lung) 4 (2%) 6 (3%)
8
Chapter 7
one additional test to screen for distant metastases (except CT of chest through liver and 
adrenals) in 42% (8 of 19, 95% CI 0.20 to 0.67).
Functional tests were evenly distributed among the two groups (Table 4), as were tests 
aiming at diagnosis and staging. In the PET arm, clinicians used two tests specifically aiming 
at distant metastases less per ten patients compared to the TWU arm (excluding PET and 
initial chest CT; mean [SD]: 0.85 [1.09] and 0.63 [1.07] TWU and PET, respectively; p=0.018). 
The number of patients which required at least one invasive procedure for mediastinal 
staging was significantly lower (p<0.0001) in favour of the PET arm. The total number of 
procedures for locoregional staging (bronchoscopy, chest CT, 18FDG PET, mediastinal staging, 
thoracotomy) was similar in both groups (mean [SD]: 3.8 [1.1] and mean [SD] 3.9 [1.1], for 
TWU and PET, respectively; p=0.081). 
Table . Number of tests and procedures for staging lung cancer (n=465) 
TWU PET P-value
All tests together (mean (sd)) 7.88 (1.95) 7.90 (1.88) 0.90
Functional tests (mean (sd)) 2.13 (0.91) 2.23 (0.94) 0.27
All staging tests (mean (sd)) 4.75 (1.53) 4.69 (1.52) 0.66
Imaging tests (mean (sd)) 3.74 (1.16) 3.80 (1.09) 0.54
Invasive tests (mean (sd)) 0.96 (0.95) 0.85 (0.79) 0.18
Invasive tests requiring general anaesthesia (mean (sd)) 0.78 (0.85) 0.59 (0.67) 0.0074
³ 1 invasive test for N staging 92 (39%) 52 (22%) <0.0001
Thoracotomy 88 (38%) 96 (41%) 0.43
Quality of staging in TWU and PET
Agreement between clinical and final stages was similar (p=0.073) with the two strategies 
(Kappa 0.85 (95% CI 0.80 to 0.90) in TWU and 0.78 (95% CI 0.72 to 0.84) in PET arm). 
Adjusted for patients suspected of having NSCLC the weighted Kappa was 0.89 (95% CI 
0.82 to 0.95) for TWU and 0.85 (95% CI 0.79 to 0.92) for PET, respectively (Table 5). 
Surgery
Of the 233 TWU patients, 79 (34%) underwent 83 mediastinoscopies, and 88 (38%) 
proceeded to thoracotomy. In the 232 patients in the PET group, mediastinoscopy was 
performed in 31 (13%) and thoracotomy in 96 (41%) patients. Of patients clinically staged 
as I/II (TWU n=85, PET n=92), 75 and 78 (TWU; PET) proceeded to surgery. Reasons for not 
performing surgery in patients classified as I/II were refusal (TWU, n=1; PET, n=2), medical 
inoperability (6 in either arm), intercurrent disease (TWU, n=1; PET, n=2), death (TWU, n=1), 
changes in planned preoperative radiotherapy or chemotherapy (TWU, n=1; PET, n=3), unclear 
diagnostic findings resulting in a wait and see policy (PET, n=1). The number of patients 
correctly staged as I/II was 65 (76%) of 85 patients in TWU arm and 64 (69%) of 92 patients 
in PET arm (p=0.4). Staging errors included benign lesions (TWU, n=3; PET, n=2), upstaging 
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Final stage 
TWU No 
data
Benign I/II IIIA IIIB M1 Metastatic
(non-lung)
Synchronous 
lung cancer
Other lung 
malignancy
All
N N N N N N N N N N
Clinical stage
No data 1 . . . . . . . . 1
Benign . 26 . . . 1 . . . 27
I/II . 3 65 6 5 3 2# . 1# 85
IIIA . . 1 16 1 1 . . . 19
IIIB . . 1 . 31 3 . . . 35
M1 . . . . . 33 . . . 33
Metastatic 
(non-lung)
. . . . . . 4 . . 4
Synchronous 
lung cancer
. . . . . . . 3 . 3
Other lung 
malignancy
. . . . . . . . 26 26
All 1 29 67 22 37 41 6 3 27 233
Final stage 
PET Benign I/II IIIA IIIB M1 Metastatic 
(non-lung)
Synchronous 
lung cancer
Other lung 
malignancy
All
N N N N N N N N N
Clinical stage
Benign 41 . . . . . . . 41
I/II 2 64 11 7 6 . . 2# 92
IIIA . . 15 . 1 . . . 16
IIIB . 1 . 16 6 1# . . 24
M1 1 . . 1 36 1# . . 39
Metastatic
(non-lung)
. . . . . 6 . . 6
Synchronous 
lung cancer
. . . . . . 3 . 3
Other lung 
malignancy
. . . . . . . 11 11
All 44 65 26 24 50 8 3 13 232
Table . Presumptive clinical diagnosis and stage compared with pathological stage or final extent of 
disease after 6 months follow-up.
# Without previously known tumour
# Without previously known tumour
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during surgery (TWU, n=10; PET, n=18), metastasis of a non-lung malignancy (TWU, n=2), 
other primary lung tumour (TWU, n=1, PET, n=2) and upstaging within 6 months follow-up 
(TWU, n=4; PET, n=6, see the following section).
Follow-up
In either group, one of the primaries  presumed benign proved to be malignant during follow-
up. Three and six (TWU; PET) patients clinically staged as I/II NSCLC had distant relapses 
within 6 months after randomisation, (ie, 5%;9 of 177) of all stage I/II patients. Of these, 
three and four (TWU; PET) relapsed after apparently curative surgery (two did not undergo 
surgery). Of the patients (TWU, n=19; PET, n=16) with pathologically proven stage IIIA, one 
and three patients (TWU; PET) were diagnosed as having stage IV disease within 6 months 
after randomisation. 
Secondary outcomes
Staging in the TWU and PET group in 22 different hospitals required a median of 23 days 
(range, 1 to 193) and 14 days (range, 1 to106) (p<0.0001). Patients in the TWU (n=88) 
and PET (n=96) group underwent thoracotomy after clinical staging at a median of 16 
(range, 4 to 116) and 18 days (range, 1 to152), respectively (excluding delayed surgery due 
to presumed benign lesions in 4 patients). Other reasons for “delayed” surgery included 
patient refusal (n=1) and co-morbidity (n=1). Morbidity due to staging procedures other 
than surgery was evenly distributed. Morbidity due to thoracotomy (including cardiac and 
cerebral events, renal insufficiency, prolonged mechanical ventilation, bleeding, infections) 
was observed in 41% and 30% (TWU and PET, respectively); p=0.17). Seven TWU (8%) and 
11 PET (11%) patients required surgical reintervention for bleeding, broncho-pleural fistula, 
irradical resection, cardiac tamponade or empyema. Sixteen (18%) and 21 (22%) patients 
(TWU and PET, respectively) were readmitted to general ward, or intensive care unit (ICU) 
within 30 days after surgery. Surgical mortality occurred in 4 TWU (4.5%) and two PET 
patients (2.1%). 
Table . Mean (sd) cost of diagnostic and therapeutic processes (dollar)
TWU PET P-value
Imaging tests 760 (467) 1964 (369) <0.01
Other tests including biopsy 904 (1050) 699 (496) 0.01
Surgery 893 (1200) 1018 (1303) 0.28
Hospitalization:
- pre-operative 1382 (2565) 889 (2406) 0.03
- post-operative 3464 (4986) 3927 (5750) 0.35
- re-admission 246 (1282) 561 (3713) 0.22
Treatment 3701 (5748) 3522 (5776) 0.74
Total 11351 (8479) 12581 (9567) 0.14
8
The PET up-front scenario
Costs 
Estimated cost of 18FDG PET was $ 1,557. Costs of diagnostic and therapeutic procedures 
were $ 11,351 in the TWU group and $ 12,581 in the PET group (p=0.14) (Table 6).
Discussion
18FDG PET has diffused into clinical practice, based predominantly on the basis of diagnostic 
accuracy studies.[13] To evaluate the effect of early diagnostic use of 18FDG PET on patient 
management and outcome, to decide whether diagnostic modalities can be replaced by 
18FDG PET, randomised clinical trials are required.[2;14;15] In this randomised trial we tested 
the hypothesis that 18FDG PET  up-front strategy reduces the number of tests to classify 
patients with a high suspicion of lung cancer. The study failed to demonstrate a reduction 
of the total number of investigations needed for TNM staging. Total costs of staging and 
therapy were equal in both arms. In patients with stage IV disease a single whole body 
18FDG PET including verification of single decisive lesion significantly reduced the number of 
tests needed for staging. 
The randomised design and the participation of physicians and patients from 22 predominantly 
community based hospitals strengthens the external validity of the study. From data of the 
National Cancer Registry we estimate that 22% of all patients diagnosed with NSCLC (stage 
I to IV) in participating hospitals were randomised, which is substantially higher than the 5 
to 9% quoted in therapy trials in lung cancer but markedly lower than the 65% in a former 
18FDG PET trial.[2;16;17] A limitation of our study was that the level of clinical experience 
with 18FDG PET  was variable among institutions. Further, due to the up-front positioning 
of 18FDG PET, 18FDG PET scans were not read in conjunction with CT which is known to 
improve the accuracy of either test.[10] This practice was enforced by the multicentric nature 
of the study with 18FDG PET  and CT being performed ‘on-site’ (allowing co-reading of scans) 
in only two of 22 hospitals. 
Even though the present study did not aim to measure impact on patient outcomes, it appears 
that there was a trend towards less futile surgery (benign lesions, per- or postoperative 
upstaging) in the TWU arm (20%) than in our previous experience.[2;12] In the PLUS trial, 
where addition of 18FDG PET  to TWU was studied, futile surgery was observed in 30% of 
patients in the conventional arm at 6 months after randomisation. Our 18FDG PET data are 
difficult to compare with other studies [2; 5; 7;18] since our key issue was substitution rather 
than added value of 18FDG PET. 
In conclusion, even though ‘up-front’ 18FDG PET in patients with (suspected) lung cancer 
does not simplify staging, it still provides good quality TNM staging with the use of less 
invasive surgery. Further research should determine whether up-front positioning of PET-CT 
(rather than PET and CT alone) might be a cost-effective alternative for current practices. 
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Summary and discussion
Samenvatting en discussie

Chapter 1 comprises an introduction and outline of this thesis. In the Netherlands lung cancer 
is still one of the most common cancer in males. On the basis of the 2000 figures of the 
Netherlands, the incidence of lung cancer was 79.8 in men and 27 in women per 100.000 
per year. Survival depends on stage, and survival at 5 years for all stages combined in the 
Netherlands is 10%. The majority of lung cancer patients have tumours histologically classified 
as NSCLC (84%). Therapy of NSCLC depends on stage, and staging depends on the quality 
of diagnostic techniques. A new diagnostic modality like 18F-fluorodeoxyglucose positron 
emission tomography (18FDG PET) in non-small cell lung cancer (NSCLC) was introduced and 
evaluated in accuracy and impact on patient management and outcome. 
The work presented here is an integral part of the research on evaluation of the role of 18FDG 
PET in NSCLC as conducted in the VU university medical centre. Typically, this research was 
done in close collaboration with other national and international university and community 
hospitals. The scientific approach in this thesis largely follows the framework to study the 
effectiveness of diagnostic tests described by van Tinteren et al. [van Tinteren, submitted]. 
This framework starts with an in-depth analysis of the size and nature of the potential residual 
inefficiency of current daily clinical practice. Then, if literature analysis reveals deficiencies in 
accuracy data of the new test, these need to be generated. If merely accuracy data of the 
new test are available, the next step is to estimate the potential impact of adding the new 
test to the diagnostic algorithm (the ‘clinical value’) in a real-life setting. At the same time, 
modelling studies are done to explore potential cost-effective applications of the new test 
which can subsequently be put to the test, preferably in a randomised design. Together, 
these steps should culminate in the development and implementation of an evidence-based 
guideline. After monitoring of its impact in terms of relevant patient outcomes at a macro-
level and assessment of the pertaining residual inefficiency, a new cycle of evaluation might 
be started which can also account for new trends in management diagnosis.
Applied to the context of staging patients suspected of potentially resectable NSCLC, we 
conducted the following studies:
Chapter 2 describes the first step in the framework in which we explored the clinical practice, 
yield and costs of preoperative staging in patients with (suspected) NSCLC in an academic and 
general hospital during a time period of two years (1993/1994). We found that in nearly 50% 
of operated patients with NSCLC, surgical treatment failed because of an irresectable tumour 
or a benign lesion during surgery, recurrence or metastases within 1 year after surgery. 
During surgery 33 (23% of patients who underwent surgery) were irresectable, 19 (13%) 
had a benign lesion. Surgery was considered as futile in 18 patients (13%) who developed 
metastases or local recurrence (n=1, 0.7%) within 12 month following radical surgery. In many 
patients, the effort of staging proved to be considerable in terms of diagnostic load (mean 
of 5 diagnostic tests (standard deviation ± 1.5) conducted over a median of 20 days and in 
13% more than 6 weeks. In many patients, the effort of staging proved to be considerable in 
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terms of diagnostic load, duration and cost, and with limited success to prevent patients to be 
subjected to surgical treatment from which they derived no obvious benefit. Failures relate to 
the quality of diagnostic work-up at every aspect of the TNM staging system.
As pointed out, one out of 7 unnecessary operations concerned patients who proved to have 
no malignancy at all. Among array of papers on the accuracy of 18FDG PET in radiologically 
indeterminate pulmonary lesions summarised in systematic reviews, we identified a lack of 
data on the accuracy of PET as a function of size. As a first approach, we reported on 
the performance characteristics of 18FDG PET as a function of pre-test risk assessment in 
radiologically indeterminate solitary pulmonary nodules (SPN) ≤10 mm on spiral computer 
tomografy in Chapter 3. In a retrospective study, we identified 35 patients with 36 SPN ≤ 
10 mm (range 3-10 mm) in diameter at clinical presentation. PET imaging correctly identified 
30 of 36 small lesions. One lesion proved to be false negative at PET and in 5 lesions, PET 
scans proved to be false positive. Specificity was 77% (17/22; 95%CI:0.55-0.92), sensitivity 
93% (13/14; 95%CI:0.66-1.0), positive predictive value 72% (13/18; 95%CI:0.46-0.90) and 
negative predictive value 94% (17/18; 95%CI:0.73-1.0). These data suggests that 18FDG PET 
imaging could be a useful tool in differentiating benign from malignant SPNs ≤10 mm (range 
3-10 mm) in diameter at clinical presentation.
The accumulated PET literature provided ample data on the diagnostic accuracy of PET in coin 
lesions but surprisingly few on the added value of PET vs. clinical probability estimates, even 
though such knowledge is a prerequisite for beneficial change in diagnostic understanding 
and therapeutic impact. Even though in daily practice most clinicians will use an intuitive 
estimate of likelihood of cancer in individual patients, the interrater variability is unknown 
and a more objective scoring system would be preferable. Swensen et al. have proposed and 
internally validated a mathematical formula which expresses the probability of malignancy 
as a function of 3 clinical (age, smoking, history of cancer) and 3 radiographic (diameter, 
spiculation, location) variables. In Chapter 4, using clinical, CT and PET data obtained in 
106 patients referred for PET for this problem, we obtained an external validation of the 
prediction model. At the same time, we quantified the potential added value of 18FDG PET 
as a function of its operating characteristics in relation to this prediction model. ROC analysis 
suggested that the best results are to be expected from the combined information of clinical 
assessment and 18FDG PET. 
To explore and improve our understanding of the potential clinical value of 18FDG PET in 
coin lesions and in a broader setting of preoperative diagnostic problems, we designed a 
“before-after study” (Chapter 5). Such clinical value studies give information to diagnostic 
understanding and influences on therapeutic decision making. Evaluation was performed by 
prospectively using questionnaires just before, immediately after and several months after the 
learning results of the 18FDG PET scan. Patients were referred to the 18FDG PET centre because 
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of suspected NSCLC, diagnostic dilemmas such as unclear radiological findings. Increased 
diagnostic understanding was reported in 84% and management changed appropriate in 
59% of cases. Cancelled surgery was the most frequently reported change in management 
(35%). Of the patients referred to resolve unclear radiological findings, improved diagnostic 
understanding or beneficial management change was reported in 46 and 71% of cases. 
In Chapter 6, using the available data on accuracy and costs of diagnostic work-up and 
therapy, we used a decision modelling approach to assess whether and how 18FDG PET 
might be cost-effective for routine use in the preoperative staging of patients with NSCLC. 
Practice variation was found between the two hospitals with regard to the setting in which 
the diagnostic staging took place and the extent of the use of mediastinoscopy. This was 
reflected in the costs and in the number of operations. Hospitalisation was the major cost 
driver in these patients. Introduction of 18FDG PET for all patients will lead to a substantial 
increase in staging costs, which are partially offset by a reduction in futile operations, give a 
certain amount of substitution of the current diagnostic work-up. 18FDG PET prior to invasive 
staging will lead to a more limited increase in staging costs, which are offset by a lower level 
of substitution of other diagnostic tests and therefore seem to be more efficient. Reserving 
18FDG PET only for patients eligible for surgery will always lead to and increase in costs. By 
declining the number of futile operations, the total costs can be contained. From a cost 
viewpoint, the evaluation of PET in a strategy after preceding diagnostic imaging but prior to 
invasive staging seemed most optimal.
Since randomised controlled trials provide most reliable and convincing evidence in estimating 
the role of 18FDG PET in the staging of NSCLC [1], we performed an RCT [2] investigating 
the added value of 18FDG PET if implemented just prior to mediastinoscopy/thoracotomy and 
a second trial (described in Chapter 7) to investigate substitutional performance of 18FDG 
PET if applied completely upfront in the diagnostic algorithm. The research question was 
whether application of 18FDG PET immediately after first presentation might simplify staging 
while maintaining accuracy, as compared to the traditional strategy in routine clinical setting. 
At first presentation patients with a provisional diagnosis of lung cancer without overtly 
dissemination were randomised to traditional work-up (TWU) according to international 
guidelines or early 18FDG PET followed by histological or cytological verification of lesions 
or imaging and follow-up. Between 1999 and 2001, 465 patients (233 TWU, 232 PET) were 
enrolled by 22 hospitals. Mean (sd) number of procedures to finalise staging was equal in 
the TWU and PET arms: 7.9 (sd:2.0) vs. 7.9 (sd:1.9); p=0.90. Agreement between clinical 
and final stage was good in both two arms (Kappa 0.85 vs. 0.78; p=0.07). The costs did not 
differ significantly. In conclusion the application of 18FDG PET up-front in staging of patients 
with (suspected) lung cancer carries similar overall quality (of accuracy) as compared to TWU, 
but does not simplify staging.
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Guideline development
In 2001, a regional multidisciplinary committee developed a preliminary guideline on the use 
of 18FDG PET in NSCLC.[3] Together with the growing availability of 18FDG PET in our region, 
this resulted in better access to 18FDG PET for this indication, and data from the regional 
comprehensive cancer centre registration subsequently showed an persistent decrease in the 
number of lung resections in the order of magnitude as predicted by the first randomised 
trial.[4]
In 2004, a national multidisciplinary committee developed evidence-based guidelines for 
diagnostic procedures and management in NSCLC.[5] 18FDG PET is recommended in patients 
with stage I/II/III disease eligible for curative surgery, after conventional work-up and 
before invasive mediastinal staging. In case of suspected locoregional or haematogeneous 
metastases verification is advised. Mediastinoscopy or endobronchial ultrasound (EBUS) or 
transoesophageal ultrasound (EUS) is advised if the primary tumour appears to be adjacent 
to the mediastinum at PET, reasoning that the spatial resolution of PET does not allow to 
separate neighbouring metastatic mediastinal nodes from the primary tumour.[6;7] In case of 
apparent primary pulmonary 18FDG avid lesions without evidence of mediastinal lymph-node 
involvement, distant or extrathoracic metastases, surgery is proposed. The implementation of 
the (new diagnostic intervention or) guideline is currently in progress in the Netherlands. An 
inventarisation for residual inefficiencies should be performed after adequate implementation 
of the guidelines and will be performed in future.
The aforementioned guidelines did not address the issue of the potential use of PET in 
clinicoradiologically indeterminate coin lesions. Therefore, using the available literature we 
suggest the following approach.
The use of 18FDG PET in clinicoradiologically indeterminate 
coin lesions ≥ 1 cm.
Data of lung cancer screening showed that helical CT is more sensitive than chest radiographs 
for detecting small nodules.[8-10] Due to these screening sessions and ongoing development 
of helical CT, more and smaller lung nodules will be detected. Considering the importance 
of identifying malignant nodules as early as possible (5-year survival in patients with resected 
non-small cell lung cancer (NSCLC) stage IA that has been resected can be 80% [11;12]), 
next step in the diagnostic algorithm should be clear. Different strategies can be followed 
like transthoracic needle biopsy, operation, a wait-and-see policy or 18FDG PET. A careful 
consideration should be made based on test performance, morbidity and costs. The chance 
of a non-diagnostic result in transthoracic needle biopsy is significant in lesions smaller than 
2 cm, and the risk of a pneumothorax is substantial (3.1- 41.7% [13]). As mentioned in this 
thesis, 15% of all operated patients showed to have a benign lesion.[14] Since a wait-and-see 
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policy carries potentially adverse effects on outcome, there is a demand for accurate non-
invasive tests to prevent surgical interventions for benign lesions. 
Adding 18FDG PET to the diagnostic work-up improves selection of surgical candidates. 
Pooled sensitivity and specificity of 18FDG PET in solitary pulmonary lesions ≥ 1 cm was 97% 
and 78%.[15;16] This implicates a probability of malignancy of 1% if pre-test probability is 
20% and 18FDG PET scanning is negative vs. a post-test probability of malignancy of 86% 
if pre-test probability is 80%. The application of 18FDG PET in these patients is related to 
the chance of changing treatment plans. Choice of treatment depends on probability of 
malignancy. This depends on clinical and radiological findings. Fischer showed that 18FDG 
PET should first be applied to populations with a pre-test probability of cancer between 10-
50%.[15] A negative 18FDG PET scan with a prevalence of 50% or lower more or less rules 
out malignant disease.
Applying 18FDG PET in a population with a higher prevalence (more than 50%), a negative 
PET would give higher post-test probability and further examinations should be performed. 
Differential diagnosis of 18FDG PET negative coin lesions include bronchioloalveolar carcinoma, 
pulmonary carcinoid tumours, metastastases from Grawitz, neuro-endocrine tumours 
etc.[17;18] In case of a wait-and-see policy, repeat radiological tests should be performed 
during 18 month. Operation should be performed in case of growth.
With subcentimeter coin lesions, typically being picked up more often nowadays due to 
low-dose CT lung cancer screening [8;19;20], the potential role of 18FDG PET needs to 
be investigated further. With respect to accuracy, this can be done relatively simple by 
performing 18FDG PET scans in selected subsets of patients with unclear CT abnormalities. 
ROC analysis is required to refine the performance characteristics of 18FDG PET as well as its 
optimal operating characteristics. The ROC curve in the meta-analysis of Gould et al. revealed 
a Q point (point on the curve closest to the left upper corner of the graph) corresponding 
with a sensitivity of 94% and a specificity of 83% (Fig 1). 
In a setting with very low pretest probabilities, it can be predicted that applying the standard 
criteria for 18FDG PET positivity would not be clinically productive (Fig 2). However, these 
predictions are indeed hypothetical since the ROC curve might be different for small lesions 
due to partial volume effects. With the development of gating technology in 18FDG PET and 
18FDG PET-CT scanners, which might also improve the quantitation of 18FDG uptake in small 
lesions, it would be desirable to conduct an accuracy study in this context. At the same time, 
clinically acceptable levels of uncertainty should be investigated, i.e. in patients as well as 
clinicians.
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Figure 2. Predicted post-test probabilities of 18FDG PET at different operating characteristics (at cut-off 
1 [the standard approach of sensitive PET reading]: sensitivity 0.94, specificity 0.77; at cut-off 2 [more 
conservative interpretation]: sensitivity 0.50, specificity 0.95). 
Figure 1. Black diamonds indicate individual study estimates of sensitivity and 1- specificity. Gray squares 
indicate maximum joint sensitivity and specificity (a global measure of test accuracy) and gray triangles 
represent the points on the receiver operating characteristic (ROC) curve at which positron emission 
tomography with 18FDG PET approximately operates in current practice for detecting malignancy in 
pulmonary nodules. Figure from Gould et al. Jama 2001.[16]
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Future aspects
PET-CT
A new advance in imaging technology is hybrid imaging instrumentation, combining 2 or more 
technologies such as PET and CT. 18FDG PET and CT provide complementary molecular and 
anatomic information, respectively, with 18FDG PET adding specificity to anatomic findings and 
CT offering precise localization of metabolic activity and, in the lung, identification of lesions 
below the detection limit of PET. Sofar, the acquisition and interpretation of the 2 image sets 
were done separately. Recently, integrated 18FDG PET-CT systems have become available; 
these systems provide 18FDG PET and CT images that are acquired nearly simultaneously and 
are capable of producing superimposed, co-registered images, facilitating interpretation. 
The most obvious advantage of PET-CT vs either technique alone in NSCLC is to distinguish 
tumour from atelectasis.[21-23] Even though there have been claims that PET-CT might add 
to the diagnosis of local tumour inoperability (defining T4), we do not expect that this will 
have a major impact on clinical management.[24] 
In SPN, respiratory and cardiac motion can cause reduced 18FDG PET signal (especially when 
located peripherally). A reduction of respiratory motion artefacts in PET imaging might be 
accomplished by respiratory gated 18FDG PET-CT.[25] When using respiratory gating the 
partial volume effect will be less so that  identification and perhaps quantification (radiotracer 
uptake e.g. SUV) of SPN might improve.[26] Gated 18FDG PET-CT in radiotherapy planning 
could improve the definition of the tumour used for radiation treatment planning and, 
therefore increase the sparing of normal tissues resulting in a reduction of side effects.
Several studies showed significant improvement of accuracy in identifying nodal metastasis 
using combined 18FDG PET and CT or hybrid 18FDG PET-CT.[27-31] Problems in repositioning 
and movement artefacts are minimised. Finally, better anatomical orientation will definitely 
improve interobserver agreement of 18FDG PET readings, which can be considerable in part 
as a function of experience [Smulders, submitted]. With the advent of alternative methods 
of invasive nodal staging (EUS, EBUS), often geographically complementary to surgical 
staging, and their likely impact on management of locally advanced IIIA patients prior and 
after induction therapy, there will be an increasing demand on imaging to provide better 
anatomical data. 
Detection of unsuspected extrathoracic metastases has already been demonstrated by 
several studies in whole-body PET imaging.[2;6;29;32] The value of combined 18FDG PET-CT 
in distant metastases could be locating, especially in unclear single focal abnormalities on 
18FDG PET. However the real advantage of 18FDG PET-CT versus 18FDG PET alone in distant 
staging needs to be verified. 
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It needs to be stressed that several technical issues with PET-CT have not been fully 
elucidated, that studies providing first-class evidence of superiority are scarce, and in this 
respect ‘l’histoire se repète’: just as with CT, MRI and PET technology rapidly diffuses into 
clinical practice apparently only slowed down by financial constraints. For those left with 
a recently purchased PET scanner, the question remains quoting Markus Schwaiger at 
the EANM congress in 2004: ‘why with the advent of new technology, the old technique 
suddenly appears so very poor’. 
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Het gebruik van 18FDG PET bij het 
niet-kleincellig longcarcinoom
Hoofdstuk 1 bevat een inleiding van dit proefschrift. In Nederland is longkanker nog steeds 
het meest voorkomende type kanker bij mannen. De incidentie van longkanker voor mannen 
is 79.8 en voor vrouwen 27 per 100.000 inwoners per jaar (op basis van getallen uit 2000). 
De gemiddelde vijf-jaarsoverleving voor longkanker in Nederland is 10%, en hangt af van de 
histologische classificatie en het stadium. Bij ongeveer 84% gaat het om een niet-kleincellig 
longcarcinoom (NSCLC). De behandeling van NSCLC wordt bepaald door het stadium van de 
ziekte op het moment van presentatie. Het vaststellen van het juiste stadium is afhankelijk 
van de kwaliteit van verschillende diagnostische technieken. Positron emission tomography 
(PET), waarbij gebruik gemaakt wordt van 18F-fluorodeoxyglucose (18FDG), is een relatief 
nieuwe beeldvormende techniek. De accuratesse van 18FDG PET bij NSCLC en de invloed op 
het patiëntenbeleid en het uiteindelijke resultaat is onderwerp voor veel studies.
Het werk dat hier gepresenteerd wordt, is een integraal deel van het onderzoek naar de rol 
van 18FDG PET bij NSCLC zoals uitgevoerd in het VU medisch centrum. Dit onderzoek werd 
verricht in nauwe samenwerking met andere nationale en internationale universiteitscentra 
en perifere ziekenhuizen. De wetenschappelijk benadering in dit proefschrift volgt het 
raamwerk ter bestudering van de effectiviteit van diagnostische testen zoals beschreven door 
van Tinteren et al.[van Tinteren, submitted]. Dit raamwerk begint met een beoordeling van de 
huidige praktijk. Daarbij worden eventuele inefficiënties van de huidige praktijk aangetoond. 
De volgende stap is analyse van de beschikbare literatuur en beoordeling van de data ten 
aanzien van accuratesse van de nieuwe test. Indien deze onvoldoende zijn, dan moeten 
deze testen alsnog verricht worden. Indien er voornamelijk accuratesse data van de nieuwe 
test beschikbaar zijn, dan is de volgende stap het beoordelen van potentiële invloed van de 
toegevoegde nieuwe test aan de diagnostische strategie (klinische waarde). Tegelijkertijd 
worden er modelmatige studies verricht ter beoordeling van kosten-effectieve toepassingen 
van de nieuwe test, welke dan getoetst kunnen worden in een gerandomiseerde studie. 
Uiteindelijk zou dit moeten leiden tot de ontwikkeling en implementatie van “evidence based”-
richtlijnen. Na de richtlijn beoordeeld te hebben zou een nieuwe evaluatie opgestart kunnen 
worden waarbij de nieuwste trends (nieuwe technieken of strategieën) ook geëvalueerd 
worden.
Het bovenstaande schema is toegepast bij de stadiëring van patiënten met een verdenking 
op NSCLC, daarbij zijn studies verricht die in de diverse hoofdstukken worden besproken:
Hoofdstuk 2 beschrijft de eerste stap in het raamwerk waarin de klinische praktijk beschreven 
wordt, opbrengst en kosten van preoperatieve stadiëring bij patiënten met (verdacht) NSCLC 
in een academisch en algemeen ziekenhuis in een tijdsbestek van 2 jaar (1993/1994). 
Chirurgische behandeling bleek onvoldoende bij bijna 50% van de geopereerde patiënten 
met NSCLC, ten gevolge van een niet resectabele tumor of een benigne afwijking tijdens 
operatie of een metastase dan wel recidief binnen 1 jaar na operatie. Tijdens operatie bleken 
33 niet resectabel (23% van de patiënten die een operatie ondergingen), 19 (13%) hadden 
een benigne afwijking. Bij 18 patiënten werd de chirurgische behandeling beschouwd als 
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futiel vanwege een metastase (13%), en bij 1 patiënt (0.7%) in verband met lokaal recidief 
binnen 12 maanden na een in opzet curatieve chirurgische behandeling. Er waren gemiddeld 
vijf (standaard deviatie ± 1.5) testen nodig om tot een uiteindelijke stadiëring te komen, in 
een tijdsbestek van 20 dagen (mediaan), bij 13% van de patiënten was meer dan 6 weken 
nodig. Bij de meeste patiënten blijkt het aantal testen, de duur en de kosten nodig ter 
stadiëring aanzienlijk te zijn. Het resultaat van de stadiëring, met als doel het voorkomen van 
onnodige operaties, is matig. 
Zoals eerder gezegd, betrof 1 van de 7 ten onrechte uitgevoerde operaties patiënten welke 
uiteindelijk geen maligniteit bleken te hebben. In de literatuur is veel geschreven over de 
accuratesse van 18FDG PET bij radiologisch onduidelijke longhaarden, er is echter zeer 
weinig geschreven over de accuratesse van 18FDG PET bij kleine longhaarden. Hoofdstuk 3 
beschrijft de karakteristieken van 18FDG PET als een functie van pre-test risico-inschatting bij 
radiologisch onduidelijke solitaire longhaarden ≤10 mm op spiraal CT-scan. 
In deze retrospectieve studie hebben wij 35 patiënten geïncludeerd met 36 solitaire 
long haarden ≤10 mm (uitersten: 3-10 mm) in diameter bij klinische presentatie. 18FDG 
PET identificeerde 30 van 36 kleine laesies correct. Een afwijking bleek fout negatief 
op18FDG PET en bij vijf laesies bleek 18FDG PET fout positief. Specificiteit was 77% 
(17/22;95% betrouwbaarheidsinterval:0.55-0.92), sensitiviteit was 93% (13/14; 95% 
betrouwbaarheidsinterval:0.66-1.0), de positief voorspellende waarde was 72% (13/18;95% 
betrouwbaarheidsinterval:0.46-0.90) en de negatief voorspellende waarde 94% (17/18; 95% 
betrouwbaarheidsinterval:0.73-1.0). Deze data suggereren dat 18FDG PET een waardevolle 
diagnostische test is ter differentiatie (benigne versus maligne) van onduidelijke solitaire 
longhaarden ≤10 mm in diameter op spiraal CT scan bij presentatie.
In de grote hoeveelheid 18FDG PET -literatuur werd overvloedig de accuratesse van 18FDG PET 
bij longhaarden beschreven en verrassend weinig over de toegevoegde waarde van 18FDG 
PET versus een klinische kansschatting ondanks dat dit van belang is voor een verbetering 
van diagnostisch begrip en de invloed op therapiekeuze. 
De meeste clinici zullen intuïtief een kansschatting maken, hoewel de variabiliteit tussen 
clinici onderling vooralsnog onbekend is, lijkt een objectiever scoringssysteem om de kans 
op maligniteit in te schatten te prefereren. Swensen et al. hebben een voorstel gedaan 
voor een intern gevalideerde wiskundige formule waarin een kansschatting op maligniteit 
weergegeven wordt als een functie van 3 klinische (leeftijd, roken, voorgeschiedenis met 
kanker) en 3 radiologische (diameter, uitlopers, locatie) variabelen. In hoofdstuk 4 beschrijven 
we een externe validatie van het voorspellingsmodel waarin we gebruik maken van CT en 
18FDG PET-data van 106 patiënten welke verwezen werden in verband met onduidelijkheid 
over de aard van de longhaard. Tegelijkertijd hebben wij de toegevoegde waarde van 18FDG 
PET gekwantificeerd als een functie van zijn operationele karakteristieken in relatie tot dit 
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predictiemodel. ROC-analyse suggereert dat de beste resultaten te verwachten zijn van 
klinische beoordeling en 18FDG PET gecombineerd. 
Ter beoordeling van de potentiële klinische waarde van 18FDG PET bij patiënten met verdachte 
longhaarden met een diagnostisch probleem, hebben wij een voor/na-studie ontworpen 
(hoofdstuk 5). Dit soort studies geeft informatie over het diagnostisch begrip en de invloed 
op therapeutisch beslissingen. Het prospectieve onderzoek bestond uit het gebruik van 
vragenlijsten voor, meteen na en enkele maanden na de resultaten van 18FDG PET. Patiënten 
werden met name verwezen naar het 18FDG PET centrum voor onduidelijke radiologische 
longhaarden, mediastinale stadiëring of onduidelijke bevindingen bij conventionele stadiëring 
ten aanzien van beoordeling van metastasen op afstand. Een toegenomen diagnostisch 
begrip werd bij 84% gerapporteerd en bij 50% van de patiënten vond een verandering van 
het therapeutische beleid plaats. Het afzeggen van een operatie werd het meest frequent 
gerapporteerd (35%). In de groep patiënten welke verwezen werden vanwege onduidelijke 
radiologische bevindingen, vond een verbetering van het diagnostische begrip bij 46% plaats 
en een zinvolle verandering van therapie bij 71% van de patiënten. 
Hoofdstuk 6 beschrijft een beslissingsmodel ter beoordeling van wanneer en hoe 18FDG PET 
kosten-effectief zou kunnen zijn bij routineus gebruik van 18FDG PET in de preoperatieve 
stadiëring van NSCLC. Praktijkvariatie werd gevonden tussen 2 ziekenhuizen met betrekking 
tot locatie waar de diagnostiek plaats vond (klinisch versus poliklinisch) en het gebruik van 
mediastinoscopie. Dit kwam terug in de kosten en in het aantal operaties. Hospitalisatie 
was de grootste kostenpost bij deze patiëntenpopulatie. Introductie van 18FDG PET voor 
alle patiënten zal leiden tot een substantiële toename van de stadiëringskosten, welke voor 
een deel “terugverdiend” worden door een daling van het aantal ten onrechte uitgevoerde 
operaties. 18FDG PET uitgevoerd voor invasieve stadiëring zal leiden tot een beperkte 
toename van kosten. Deze beperking komt met name door substitutie van diagnostische 
testen. Er zal altijd een toename in kosten plaatsvinden wanneer 18FDG PET alleen gebruikt 
zal worden voor patiënten met NSCLC welke een operatie kunnen ondergaan. Met name 
door vermindering van het aantal ten onrechte uitgevoerde operaties kunnen de kosten 
beperkt worden. Vanuit het perspectief van kosten is het gebruikt van 18FDG PET bij NSCLC 
het meest optimaal na beeldvormende diagnostiek en voor de invasieve stadiëring. 
De meest betrouwbare en overtuigende informatie ten aanzien van de rol van 18FDG PET 
in het stadiëringstraject van NSCLC is gerandomiseerd onderzoek.[1] Wij hebben een 
gerandomiseerde trial [2] uitgevoerd ter bestudering van de toegevoegde waarde van 18FDG 
PET net voor invasief mediastinaal onderzoek of thoracotomie en een tweede trial (beschreven 
in hoofdstuk 7) ter beoordeling van de rol van 18FDG PET vroeg in het diagnostische traject 
gepositioneerd. Daarbij werden ook de substitutiemogelijkheden van 18FDG PET beoordeeld. 
De onderzoeksvraag was of de toepassing van 18FDG PET meteen na eerste presentatie, het 
stadiëringstraject zou kunnen vereenvoudigen zonder aan accuratesse te verliezen. Controle-
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arm was de standaard (conventionele) stadiëringsstrategie (volgens internationale richtlijnen) 
zonder 18FDG PET. Patiënten werden gerandomiseerd direct na eerste verdenking op NSCLC 
(patiënten met bij eerste presentatie duidelijk gemetastaseerde ziekte werden uitgesloten), 
vervolgens volgde histologische of cytologisch verificatie van afwijkingen of beeldvormende 
diagnostiek en follow-up. 
Tussen 1999 en 2001 werden 465 patiënten (233 conventionele arm, 232 PET arm) 
geïncludeerd door 22 ziekenhuizen. Het gemiddelde (standaard deviatie) aantal verrichtingen 
wat nodig was voor stadiëring in de 2 armen (conventioneel en PET) was 7.9 (2.0) vs. 7.9 
(1.9); p=0.90. Overeenkomst tussen klinische stadiëring en de stadiëring na operatie of 
FU was goed in beide armen (Kappa 0.85 vs. 0.78; p=0.07). De kosten verschilden niet 
significant. We kunnen concluderen dat het gebruik van 18FDG PET vroeg in het stadiërings–
traject bij patiënten met (verdenking op) NSCLC gelijke kwaliteit heeft vergeleken met de 
conventionele arm, en geen vereenvoudiging van stadiëring geeft.
Richtlijnontwikkeling
In 2001 werd een voorlopige richtlijn voor het gebruik van 18FDG PET bij NSCLC samengesteld 
door een regionale multidisciplinaire commissie.[3] Samen met de groeiende beschikbaarheid 
van 18FDG PET in onze regio, resulteerde dit in een betere toegang tot 18FDG PET voor 
deze indicatie. Data vanuit het Integraal Kanker Centrum Amsterdam lieten een blijvende 
daling zien van het aantal longresecties in de orde van grootte zoals voorspeld in de eerste 
gerandomiseerde trial.[4]
In 2004 werden ”evidence based”richtlijnen voor het diagnostische traject en behandeling 
van NSCLC ontwikkeld door een nationaal multidisciplinaire commissie.[5] 18FDG PET wordt 
geadviseerd bij patiënten met stadium I/II/III NSCLC die in aanmerking komen voor curatieve 
therapie, na conventionele work-up en voor invasieve mediastinale stadiëring. Bij verdenking 
op locoregionale of haematogene metastasen wordt verificatie geadviseerd. Mediastinoscopie 
of endobronchiale echo (EBUS) of transoesophageale echo (EUS) wordt geadviseerd indien 
de primaire tumor tegen het mediastinum aan ligt op 18FDG PET. Door de resolutie van 18FDG 
PET kan geen onderscheid gemaakt worden tussen aanpalende klieren of primaire tumor bij 
centrale tegen het mediastinum aanliggende tumoren.[6,7] Bij tumoren die 18FDG opnemen, 
zonder dat er aanwijzingen zijn voor mediastinale dan wel afstandsmetastasen, wordt 
chirurgie geadviseerd. Op moment van schrijven wordt de nieuwe richtlijn geïmplementeerd. 
Na implementatie zal ook deze richtlijn getoetst moeten worden op tekortkomingen. 
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Klinisch en radiologisch onduidelijke coin-laesies komen niet aan bod in bovengenoemde 
richtlijn. Gebruik makend van de beschikbare literatuur, zouden wij de volgende benadering 
willen voorstellen.
Het gebruik van 18FDG PET bij klinisch en radiologisch onduidelijke 
coin-laesies ≥ 1 cm
Data van longkanker screening laten zien dat spiraal CT sensitiever is dan röntgenfoto’s van de 
longen bij het opsporen van kleine afwijkingen.[8-10] Ten gevolge van deze screenings-studies 
en de verder gaande ontwikkeling van CT zullen er meer en kleinere longafwijkingen ontdekt 
worden. Het is van belang om zo snel mogelijk te beoordelen of zo’n coin-laesie maligne is, 
gezien de goede vijf-jaarsoverleving jaars overleving bij patiënten met een stadium IA NSCLC 
(80% [11;12]). De volgende stap in het diagnostische traject moet duidelijk zijn. Verschillende 
strategieën kunnen gevolgd worden zoals transthoracale naaldbiopsie, operatie, afwachtend 
beleid of 18FDG PET. De keuze zal afhangen van de sensitiviteit en specificiteit van een test, 
morbiditeit en de kosten. De kans op een niet-diagnostisch resultaat bij een transthoracaal 
naaldbiopt is aanzienlijk bij afwijkingen kleiner dan 2 cm, het risico op een pneumothorax is 
ook aanwezig (3.1- 41.7% [13]). 
Zoals eerder genoemd in dit proefschrift had 15% van alle geopereerde patiënten een 
goedaardige afwijking.[14] 
Afwachtend beleid draagt het risico met zich mee, dat het uiteindelijk toch om een maligne 
aandoening gaat, waarbij afwachten mogelijk ongunstig voor de behandeling zou kunnen 
zijn. Daarom is er behoefte aan accurate niet-invasieve testen ter voorkoming van chirurgische 
interventies voor benigne afwijkingen. 
Selectie van chirurgische kandidaten zou verbeterd worden indien 18FDG PET toegevoegd 
wordt aan het diagnostische traject. Samengevoegde sensitiviteit en specificiteit van 18FDG 
PET bij solitaire longhaarden ≥ 1 cm was 97% en 78%.[15] Dit impliceert een kans op 
maligniteit van 1% wanneer de pre-test kansschatting 20% is en het 18FDG PET resultaat 
negatief is versus een post-test kans op maligniteit van 86% wanneer de pre-test kans 80% is. 
Het gebruik van 18FDG PET bij deze patiënten is gerelateerd aan de kans op verandering van 
het therapeutische plan. De keuze van behandeling is afhankelijk van de kans op maligniteit. 
Dit hangt af van klinische en radiologische bevindingen. Fischer liet eerder zien dat 18FDG 
PET gebruikt moet worden in een populatie met een pre-test kans op kanker tussen de 10 
en 50%.[15;16] Een negatieve 18FDG PET-scan met een prevalentie van 50% of minder sluit 
een maligniteit uit. Wanneer 18FDG PET gebruikt wordt in een populatie met een hogere 
prevalentie (meer dan 50%), dan zou een negatieve 18FDG PET-scan een hoger post-test 
kans op maligniteit geven en moet aanvullend onderzoek verricht worden. Bij 18FDG PET 
negatieve coin-laesies kan differentiaal diagnostisch gedacht worden aan bronchioalveolair 
cel carcinoma, carcinoid, metastase van Grawitz, neuro-endocriene tumoren etc.[17,18] 
Indien een afwachtend beleid aangehouden wordt, dan zouden radiologische testen herhaald 
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Figuur 1. De zwarte ruitjes laten de individuele studie resultaten zien (sensitiviteit en 1-specificiteit). Het 
grijze vierkantje geeft een indicatie van de maximum “joint” sensitiviteit en specificiteit (een globale maat 
voor accuratesse). Het grijze driehoekje is het Q-punt op de ROC-curve van 18FDG PET in de huidige praktijk 
ten aanzien van het detecteren van maligne longhaarden. Figuur van Gould et al. Jama 2001.[16]
Figuur 2. Voorspelde post-test kansschatting van 18FDG PET bij verschillende uitvoerings-karakteristieken 
(1 afkapwaarde volgens de standaard manier sensitief PET beoordelen: sensitiviteit 0.94 en specificiteit 
0.77; 2 meer conservatieve interpretatie van afkapwaarde: sensitiviteit 0.50 en specificiteit 0.95).
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moeten worden gedurende 18 maanden. Indien de afwijking groeit, moet gekozen worden 
voor een operatie (verificatie). 
18FDG PET bij coin-laesies die kleiner zijn dan 1 cm moet nog beter bestudeerd worden. 
Accuratesse zou eenvoudig beoordeeld kunnen worden bij een geselecteerde subset 
van patienten met onduidelijke radiologische bevindingen op CT. Voor de uiteindelijke 
uitvoeringskarakteristieken zijn ROC-analyses nodig. Het Q-punt (het punt op de curve welke 
het dichtste bij de linker bovenhoek ligt op de grafiek) bij Gould en anderen correspondeerde 
met een sensitiviteit van 94% en een specificiteit van 83% (Figuur 1).
Het is waarschijnlijk dat bij lage pre-test kansschatting een 18FDG positieve PET-scan volgens 
de standaard criteria niet richting gevend is (Figuur 2). Deze voorspellingen zijn hypothetisch, 
ROC-curven zouden anders kunnen zijn voor kleine afwijkingen door ‘partial volume’ effect. 
Sinds kort is er ook de mogelijkheid tot ‘gating’ bij 18FDG PET en 18FDG PET-CT scanners. 
Studies ter beoordeling van accuratesse maar ook kwantificatie van 18FDG opname in kleine 
laesies met de huidige PET-scanners en de nieuwere technieken (gated 18FDG PET en 18FDG 
PET-CT) zijn zeer wenselijk. Tegelijkertijd zou de maat van onzekerheid wat de patiënt maar 
ook de dokter zou willen/kunnen accepteren onderzocht moeten worden. 
Toekomst
PET-CT
Een nieuwe ontwikkeling in de beeldvormende diagnostiek is het combineren van 2 of meer 
technieken zoals 18FDG PET en CT. Tot nu toe werden deze 2 technieken apart uitgevoerd 
en beoordeeld. Sinds kort zijn er ook geïntegreerde 18FDG PET-CT-systemen. Deze systemen 
produceren 18FDG PET- en CT-beelden welke nagenoeg simultaan verkregen zijn, wat de 
interpretatie van de beelden vereenvoudigd en mogelijk ook verbeterd.
Het belangrijkste voordeel van 18FDG PET-CT versus beide technieken separaat bij NSCLC 
is de mogelijkheid om onderscheid te maken tussen tumor en atelectase.[19] Hoewel er 
geluiden opgaan dat 18FDG PET-CT bij kan dragen ten aanzien van het beter beoordelen van 
tumorgrootte (met name T4) verwachten wij niet dat dit een belangrijke invloed heeft op het 
klinische beleid.[20] 
Bij solitaire longhaarden kan het ademen en de hart-activiteit een verminderd 18FDG-signaal 
geven. Een vermindering van bewegings-artefacten door ademen zou bereikt kunnen 
worden door ‘gated’ 18FDG PET-CT.[21] Het ‘partial volume’ effect zou minder kunnen zijn 
zodat identificatie en mogelijk ook kwantificatie van SPN zou kunnen verbeteren.[22] Het 
beter beoordelen van de tumorgrootte (T stadium) en minder bewegingartefact ten gevolge 
van ‘gating’ zou ook bij de radiotherapieplanning van voordeel kunnen zijn, waarbij meer 
normaal weefsel gespaard kan worden met daardoor minder bijwerkingen. 
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Verschillende studies laten een verbetering zijn van accuratesse ten aanzien van het identificeren 
van mediastinale metastasen bij het gebruik van 18FDG PET-CT.[23-27] Uiteindelijk zal een 
betere anatomische oriëntatie leiden tot een verbetering van interobserver overeenkomst van 
het beoordelen van 18FDG PET [Smulders et al, submitted]. 
Met de komst van nieuwe minder invasieve technieken ter beoordeling van mediastinale 
lymfklieren (EUS, EBUS) zal er ook meer vereist worden van beeldvormende technieken om 
betere anatomische data te verkrijgen. Mogelijk speelt 18FDG PET-CT daar ook een rol bij.
De meerwaarde van 18FDG PET-CT bij afstandsmetastasen zou kunnen liggen bij het beter 
lokaliseren, met name bij onduidelijke solitaire afwijkingen op afstand. Het echte voordeel van 
18FDG PET-CT ten opzichte van 18FDG PET alleen bij het beoordelen van afstandsmetastasen 
moet nog bewezen worden.
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Met andere woorden…
Longkanker is nog steeds een van de meest voorkomende vormen van kanker. Per jaar 
wordt in Nederland bij ruim 8000 nieuwe patiënten longkanker gediagnosticeerd.[1] Er 
zijn verschillende typen longkanker. Verreweg het grootste aandeel (84%) van longkanker 
wordt histologisch geclassificeerd als niet-kleincellig longkanker. De 5-jaars overleving voor 
niet-kleincellig longkanker onafhankelijk van het stadium van voortschrijding van de ziekte 
is 10%. Het hoge aantal sterfgevallen wordt veroorzaakt doordat longkanker heel vaak pas 
in een gevorderd stadium wordt ontdekt waardoor een genezende behandeling niet meer 
mogelijk is. De behandeling en prognose van niet-kleincellig longkanker zijn afhankelijk van 
het stadium, dat wil zeggen de mate van uitzaaiingen. Hierbij gaat het om de grootte en 
uitbreiding van de tumor (lokaal), uitzaaiingen naar lymfklieren en/of uitzaaiingen naar 
andere organen in het lichaam (bijvoorbeeld bot of lever). Om het stadium te bepalen 
zijn bepaalde onderzoeken nodig: dit kunnen beeldvormende technieken zijn zoals een 
röntgenfoto, computertomografie (Figuur 1) of meer invasief zoals het verkrijgen van weefsel 
door middel van bijvoorbeeld een operatie. Aan de hand van deze onderzoeken wordt 
bepaald of een patiënt in aanmerking komt voor een operatie, radiotherapie, chemotherapie 
of een gecombineerde behandeling (bijvoorbeeld chemotherapie en een operatie). 
In hoofdstuk 2 wordt dit proces van stadiering beschreven in twee ziekenhuizen tussen 1993 
en 1994. Deze studie laat zien dat het traject langdurig en ingewikkeld kan zijn met een niet- 
optimaal resultaat. Er waren in dit onderzoek gemiddeld vijf testen (in ongeveer 20 dagen) 
nodig voor het bepalen van het stadium. Uiteindelijk blijkt dat de helft van de patiënten 
ten onrechte geopereerd is. Tijdens de operatie bleek bij 23% van de patiënten de tumor 
niet volledig verwijderd te kunnen worden, bij 13% van de patiënten er een goedaardige 
afwijking te zijn en werd bij 13% van de patiënten binnen 12 maanden na de operatie een 
uitzaaiing gevonden. Bij 50% van de geopereerde patiënten bleek het uiteindelijke stadium 
(bij operatie en follow-up) niet overeen te komen met het stadium bepaald voorafgaand aan 
de operatie. 
Sinds een aantal jaren is er een nieuwe beeldvormende techniek, 18F-fluorodeoxyglucose 
positron emissie tomografie (18FDG PET), waarbij met name de stofwisselingsprocessen 
zichtbaar gemaakt worden, dit in tegenstelling tot bijvoorbeeld computertomografie waarbij 
informatie verkregen wordt over grootte en vorm van de afwijkingen. 
Kankercellen hebben een verhoogde stofwisseling en nemen onder andere meer glucose 
op dan andere cellen. Door glucose te koppelen aan een radioactief fluoratoom (18F) wordt 
een radioactieve verbinding verkregen: 18FDG. Na injectie via een ader en verspreiding in het 
lichaam via de bloedbaan, zal dit radioactieve glucose zich vooral in een orgaan of weefsel met 
een verhoogde stofwisseling ophopen. Door middel van een PET-camera kan deze verhoogde 
stofwisseling (“hotspot”) in beeld gebracht worden. Daarbij wordt het hele lichaam gescand 
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in tegenstelling tot andere beeldvormende 
technieken waarbij doorgaans maar een deel 
van het lichaam wordt onderzocht (Figuur 1). 
Eerder onderzoek laat zien dat een 18FDG PET-
scan beter zou kunnen zijn voor het in kaart 
brengen van het stadium bij niet-kleincellig 
longkanker. Omdat de 18FDG PET-scan ook 
niet perfect is, ook ontstekingen kunnen 
een hotspot geven, moeten de hotspots 
bevestigd worden door microscopisch 
weefselonderzoek.
Door verbetering van technieken en breder 
inzetten van bepaalde technieken (bijvoorbeeld 
computer tomografie als routineonderzoek 
van bevolkingsgroepen met een verhoogd 
risico op ontwikkeling van longkanker) 
zullen er ook meer longafwijkingen 
gevonden worden waarvan op radiologisch 
criteria het onduidelijk is wat de aard van 
deze afwijkingen is. Deze radiologisch 
niet te classificeren longafwijkingen 
kunnen ook modelmatig bekeken worden. 
Hoofdstuk 3 laat een model zien van een 
kansschatting naar kwaadaardigheid van 
onduidelijke longafwijkingen (≤ 3 cm) op 
computertomografie. Hierbij wordt gebruikt 
gemaakt van bepaalde kenmerken van 
longkanker op computer tomografie (locatie, 
vorm, diameter van afwijking) en klinische 
kenmerken (leeftijd, wel of niet roken, wel 
of geen kanker gehad). Dit reeds eerder 
beschreven model combineren we met 
18FDG PET. Dit onderzoek laat zien dat de 
combinatie van de klinische en radiologische 
kenmerken en het resultaat van 18FDG PET 
een goede combinatie is voor de voorspelling 
(goed- of kwaadaardig) van onduidelijke 
longafwijkingen.
Figuur 1. A. Röntgen foto van de longen. Geen 
duidelijke afwijking zichtbaar.
Figuur 1. C. 18FDG PET scan, normale opname in 
hersenen, nieren en blaas. Hotspot in rechter long.
Figuur 1. B. Computer tomografie van de longen.
Pijl: verdachte afwijking voor longkanker in 
longweefsel.
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Naast een toename in het aantal radiologisch moeilijk te classificeren longhaarden is het 
ook mogelijk om steeds kleinere tumoren te ontdekken. Het beoordelen van kleine perifere 
afwijkingen in de longen is eveneens een moeilijk proces. Bij computer tomografie wordt zo 
goed mogelijk een beoordeling gegeven (kwaadaardig, goedaardig, onduidelijk) aan de hand 
van verschillende criteria. Met name de onduidelijke longafwijkingen geven vaak aanleiding 
tot veel onderzoek en soms ook operaties welke achteraf niet nodig blijken te zijn. Hoofdstuk 
4 beschrijft de waarde van 18FDG PET bij deze kleine (≤10 mm) op computertomografie niet 
te classificeren afwijkingen. 18FDG PET kon in 93% van de afwijkingen de afwijking ook 
daadwerkelijk zichtbaar maken en in 77% van de afwijkingen was deze afwijking correct 
beoordeeld als goed- of kwaadaardig. Ook bij deze kleine (≤10 mm) afwijkingen lijkt 18FDG 
PET zeker van aanvullende waarde. 
Wanneer nieuwe technieken gebruikt worden is het ook belangrijk dat ze beoordeeld worden 
in de praktijk. Wat zijn bijvoorbeeld de redenen voor 18FDG PET-gebruik, hoe nuttig vond de 
aanvrager deze 18FDG PET-scan en is er wat veranderd in het beleid? Een manier om dit te 
beoordelen is door middel van vragenlijsten voor, direct na en ruim na het maken van een 
18FDG PET-scan. In hoofdstuk 5 beschrijven we deze aanpak en de resultaten hiervan bij 
de evaluatie van longkanker. Patiënten in dit onderzoek werden met name verwezen naar 
het klinisch PET-centrum vanwege onduidelijke bevindingen bij beeldvormend onderzoek. 
Artsen rapporteerden in 84% een beter begrip en er vond in 59%, naar aanleiding van 
het PET-resultaat, een gunstige beleidsverandering plaats. De belangrijkste therapeutische 
consequentie naar aanleiding van de uitslag van de 18FDG PET-scan was het afzeggen van 
een operatie (in 35% van de patiënten).
18FDG PET-scan is kostbaar en niet overal vrij beschikbaar. Gezien de beperkte capaciteit 
in Nederland moet bepaald worden voor welke groep patiënten deze onderzoekstechniek 
zinvol is. Aan de hand van eerder onderzoek werd een model ontwikkeld om de invloed van 
18FDG PET te bepalen op de stadiering bij niet-kleincellig longkanker en zicht te krijgen op 
de kosten. Hoofdstuk 6 laat op een modelmatige manier zien dat 18FDG PET bij de stadiering 
van niet-kleincellig longkanker kosteneffectief is na beeldvormend onderzoek en voor invasief 
onderzoek. Het nadeel van een kosten-effectiviteits studie is, is dat deze gebaseerd is op een 
aantal aannames. Een manier om dit te omzeilen is een vergelijkende studie waarbij de ene 
groep patiënten een PET scan krijgt en de andere groep geen PET scan. 
Het laatste hoofdstuk (hoofdstuk 7) in dit proefschrift beschrijft de studie waarbij gekeken 
is of het stadiëringstraject bij patiënten met (verdenking op) niet-kleincellig longkanker 
eenvoudiger gemaakt kan worden (bijvoorbeeld weglaten van bepaalde onderzoeken) 
zonder minder nauwkeurig te worden. Hiervoor is een vergelijkende studie gedaan tussen de 
“traditionele” stadiering volgens de internationale richtlijnen (dit is zonder 18FDG PET-scan) en 
de stadiering waarbij gebruik gemaakt werd van 18FDG PET-scan direct nadat bekend werd 
11
Samenvatting en discussie
dat er een verdachte afwijking op de foto zichtbaar was. Het aantal onderzoeken dat nodig 
was voor het bepalen van het stadium en de kosten van onderzoek en behandeling, was in 
beide groepen gelijk. De duur van het onderzoekstraject was beduidend korter in de 18FDG 
PET-groep. Beide groepen waren even nauwkeurig ten aanzien van het juist bepalen van 
het stadium. We kunnen stellen naar aanleiding van dit onderzoek dat het vroege gebruik 
van 18FDG PET in het traject van stadiumbepaling (direct na het maken van de longfoto) de 
kwaliteit van stadiumbepaling niet beïnvloedt en dit proces niet vereenvoudigd vergeleken 
met de traditionele manier. 
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Vereniging van Integrale Kankercentra; 2002.
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Uiteindelijk ligt het proefschrift dan toch voor u. Het verboden P-woord mag weer uitgesproken 
worden. Dit proefschrift is tot stand gekomen dankzij de inspanningen en samenwerking van 
heel veel collega’s. Het was een voorrecht om op twee afdelingen (nucleaire geneeskunde 
en longziekten) te mogen werken en met veel collega’s uit andere ziekenhuizen te kunnen 
samenwerken. Een belangrijk deel van dit proefschrift is klinisch gericht onderzoek, daar 
hebben veel patiënten belangeloos aan meegewerkt. Al deze mensen ben ik zeer dankbaar. 
Professor dr. PE Postmus, beste Piet, erg blij was ik dat je me een kans gaf voor de opleiding 
tot longarts en de mogelijkheid om te promoveren. Op cruciale momenten tijdens het 
onderzoek maar ook binnen de opleiding tot longarts, gaf je me een zet in goede richting. 
Professor dr. GJ Teule, beste Jaap, hoe druk je het ook had, er was eigenlijk altijd ruimte voor 
een filosofisch getint gesprek ergens tussendoor op weg van A naar B. Niet alleen voor de 
activiteiten op de werkvloer maar vooral ook voor bezigheden buiten het werk om heb je een 
brede belangstelling (zelfs de componist Kagel kreeg een kans). Dank voor al je inzicht.
Professor dr. OS Hoekstra, beste Otto, hoeveel tijd heb jij wel niet in dit proefschrift gestoken. 
En hoe vaak heb ik niet gehoord: “We doen het helemaal anders”. Na heel wat re-analyses, 
herschrijven met behulp van jouw creativiteit ligt er nu toch maar een proefschrift! Je inzicht 
en bevlogenheid is erg aanstekelijk. Ik ben nog steeds blij met onze samenwerking. 
Professor dr. EF Smit, beste Egbert, het kritisch denken is erin gestampt door jou. Bij elke 
vraag een wedervraag. Je scherpe maar ook praktische aanpak bij knelpunten was en is 
erg verhelderend. Dat geldt voor zowel de wetenschap als de kliniek. Daarnaast is het ook 
gewoon prettig om met jou samen te werken. 
De leescommissie Prof. dr. H Groen, Prof. dr. M Boers, Prof. dr. J Vansteenkiste en dr. P Jager. 
U wil ik danken voor uw aandacht en de tijd die u genomen heeft voor dit proefschrift. 
Alle collega’s uit de perifere ziekenhuizen en het AZG zou ik willen bedanken voor hun 
bijdrage aan onder andere de POORT-studie. Hoe lastig het ook soms was, uiteindelijk 
hebben jullie 465 patiënten gerekruteerd. Dankzij jullie inspanning hebben we deze studie 
uit kunnen voeren. 
De medewerkers van het IKA zou ik willen danken voor hun inzet voor de POORT-studie. Met 
name mevr G Smit en mw S de Ruiter, Gertruud en Stella, dank voor jullie grenzeloze inzet 
en jullie aangename gezelschap tijdens de eindeloze controles van de database. Jullie hebben 
mij flink bijgespijkerd ten aanzien van databases. 
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De eerste mijlpaal, mijn eerste internationale publicatie samen met drs. P van Velthoven en 
drs. J van den Bergh. Dank voor jullie hulp.
Mw EW Grijseels, mw C Uyl de Groot en dhr P Verboom, beste Els Carin en Paul. Dank voor 
jullie vakkundige kosten analyses. 
Computer tomografie beelden beoordelen, dat doe je met drs R Golding, in de weekeinden 
nog een keer alle beelden bekijken. Erg leerzaam. Bedankt.
Dr. E Comans, Emile, fijn dat je altijd bereid was en bent een PET scan te beoordelen.
Drs J van Mourik en Dr MA Paul wil ik danken voor hun adviezen en vertrouwen ten aanzien 
van de POORT studie.
Dhr H van Tinteren, beste Harm, wat fijn dat je me eigenlijk altijd gerust kon stellen als ik 
dacht dat ik weer iets statistisch relevants over het hoofd gezien had. De tijdstippen dat ik je 
met mijn bedenksels lastig gevallen heb, waren volgens mij statistisch significant vaker net 
voor jou vakantie. Ondanks dat toch altijd een pasklaar antwoord.
Dr. A van Lingen, beste Arthur, computers en dergelijke blijven grote mysteries voor mij, blij 
dat jij met regelmaat een mysterie hebt op kunnen lossen. Jouw relativeringsvermogen en 
jouw steun in de rug zijn altijd erg welkom. 
Veel administratief werk is verricht door mw A Kalwij, mw C Karga (PET centrum) en mw A 
Kijk in de Vegte. Beste Amanda, Cemile en Anny dank voor al jullie hulp bij al die klusjes die 
toch maar gedaan moeten worden. 
De andere opleiders in het VUMC, dr. G Sutedja, dr. A Boonstra, dr. A Vonk Noordegraaf en 
dr. P Kunst wil ik danken voor hun geduld. Opleiden lijkt mij niet makkelijk… al die eigenwijze 
assistenten. Over enkele maanden kom ik terug voor de finishing touch! 
Mijn kamergenoten Ben Venmans, Ton van Boxem, Cas Colder, Nel Hagen, Roderick Breuer, 
Igor Krivokuca, Hugo Rutten, Michel van de Heuvel, Wouter Jacobs, Hes Brokx, Arjen Winkel 
en Arifa Moons wil ik danken voor hun geduld wanneer ik weer stuiterend de kamer binnen 
kwam. Lekker klagen maar vooral ook veel gelachen.
De medewerkers van de behandelkamer en longfunctie, Linda Penninx, Hanneke Motman, 
Andy, Herman Groepenhoff, Gwenda Commandeur, Joost Admiraal en Wilma de Ruiter. Ik 
ben blij dat jullie zo nu en dan een onvolledig ingevuld formulier door de vingers zagen. Door 
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drukte moet je soms aan triage doen. Inmiddels weer op volle sterkte, zodat ik straks alles 
goed kan maken.
Het PET centrum met mw S van Baalen, dhr R Coopmans en destijds dhr B Hoving. Beste 
Suzette, Rob en Bas, dank voor jullie harde werken en de altijd lieve aandacht voor de 
patiënten. 
Zeven c (onder leiding van Marieke Catz en Natasja Kok) en acht b (onder leiding van 
Frits Stricker) mag ik niet vergeten. De longafdelingen, met een geweldig team van 
verpleegkundigen. Het is een plezier om samen met jullie de afdeling te “runnen”.
Collegae onderzoekers Bart Wittgen, Bas Holverda, Roald Roeleveld, Tji Tan, Jan-Willem 
Lankhaar, Remco van den Berg en Serge van Wolferen. De vrolijke noten van de afdeling. 
Onderzoek is taai en daarom heb je elkaar nodig om veel en hard te lachen, elke keer weer. 
De collega’s van mijn huidige werkplek het OLVG afdeling longziekten wil ik bedanken 
voor de vrije tijd die ik kreeg t.a.v. de afronding van dit proefschrift en voorbereiding op de 
promotie.
Graag wil ik huidige opleiders ten aanzien van het perifere deel van de opleiding tot longarts 
in het OLVG, dr. B Kwa, dr. W Hamersma, dr. F Krouwels, drs. F Toben, drs. K Liesker danken 
voor hun hartelijke en open ontvangst als nieuwe assistent. 
De opleiders en alle collega assistenten van de afdeling interne geneeskunde uit het Sint 
Antonius ziekenhuis te Nieuwegein wil ik danken voor de twee erg leuke en leerzame jaren. 
Ik hoop dat dit proefschrift de vraag van dr. H Haanen (“wat moet je nou met zo’n PET 
scan?”) beantwoord. 
Een van de weinige mensen die ik nooit gestresst heb gezien is Chris Bor, hij heeft de gehele 
lay-out verricht. Dat gaf erg veel rust. Bedankt. 
Een van mijn lieve vrienden Alex de Jong heeft een prachtig schilderij gemaakt. Een detail 
hiervan heb ik gebruikt voor de omslag. Met het woord wetenschap ben je aan de slag 
gegaan, met resultaat. Dank.
Mijn paranimf dr. C Hoekstra, Corneline, is altijd trouw geweest. Ondanks thuisdrukte genoeg 
tijd om even naar Utrecht te komen. Inmiddels geen directe collega meer, maar gelukkig nog 
steeds een heel goede vriendin. 
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Familie, vriendin en paranimf, drs. FE Jansen. Floortje, ik ben blij dat je naast alle andere life-
events ook dit moment van dichtbij mee wil maken. Binnenkort sta ik jou terzijde. 
Al mijn lieve vrienden, vriendinnen en familie, voor veel van jullie was ik de afgelopen periode 
niet erg bereikbaar. Het goede voornemen is er, om daar verandering in te brengen.
Jaap Tuijn, veel geoefend, herhaald, verbeterd, gelachen om mijn uitspraak. Samen de stress 
momenten doorstaan. Altijd bereid te helpen. Fijn dat je naast me stond.
Robert en Esther Herder, met een relativeringsvermogen als geen ander. Heel prettig wanneer 
ik door de bomen het bos niet meer zag. 
Mijn lieve ouders, jullie krijgen alle dank voor alles wat jullie mij gegeven hebben. De 
mogelijkheid om te kunnen studeren, het tomeloze vertrouwen en alle andere wijsheden. 
Zonder jullie zou ik hier niet staan. 
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AUC area under the curve
AIC Akaike’s information criterion
BGO bismuth germanium oxide
CI confidence interval
CT computed tomography
DU diagnostic understanding
ECOG eastern co-operative oncology group
18FDG  18F-fluorodeoxyglucose
FU follow-up
IQR inter quartile range
MCA medical centre Alkmaar
MRI magnetic resonance imaging
NCR national cancer registry
NPV negative predictive value
NSCLC non-small cell lung cancer
OSEM ordered subset expectation maximisation
PALGA pathological anatomical national register
PET positron emission tomography
PPV positive predictive value
ROC receiver operating characteristic
SCLC small cell lung cancer
SD standard deviation
SPN solitary pulmonary nodule
SUV standardised uptake value
TC treatment choice
TNM tumour node metastasis
T/N ratio tumour normal tissue ratio
TWU traditional work-up
VUMC VU university medical centre
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